CN112552352A - Organic electroluminescent material and device - Google Patents

Organic electroluminescent material and device Download PDF

Info

Publication number
CN112552352A
CN112552352A CN202011044860.7A CN202011044860A CN112552352A CN 112552352 A CN112552352 A CN 112552352A CN 202011044860 A CN202011044860 A CN 202011044860A CN 112552352 A CN112552352 A CN 112552352A
Authority
CN
China
Prior art keywords
compound
group
ring
fused
integer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011044860.7A
Other languages
Chinese (zh)
Inventor
姬志强
皮埃尔-吕克·T·布德罗
辛卫春
沃尔特·耶格尔
伯特·阿莱恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universal Exhibition Co
Universal Display Corp
Original Assignee
Universal Exhibition Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/022,151 external-priority patent/US20210098717A1/en
Application filed by Universal Exhibition Co filed Critical Universal Exhibition Co
Publication of CN112552352A publication Critical patent/CN112552352A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0033Iridium compounds
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/06Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K50/00Organic light-emitting devices
    • H10K50/10OLEDs or polymer light-emitting diodes [PLED]
    • H10K50/11OLEDs or polymer light-emitting diodes [PLED] characterised by the electroluminescent [EL] layers
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/30Coordination compounds
    • H10K85/341Transition metal complexes, e.g. Ru(II)polypyridine complexes
    • H10K85/342Transition metal complexes, e.g. Ru(II)polypyridine complexes comprising iridium
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/18Metal complexes
    • C09K2211/185Metal complexes of the platinum group, i.e. Os, Ir, Pt, Ru, Rh or Pd

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Electroluminescent Light Sources (AREA)

Abstract

The present invention relates to organic electroluminescent materials and devices. Disclose a kind ofI
Figure 1
First ligand L ofAThe compound of (1). In formula I, ring B is a 5 or 6 membered ring; x1、X2And X3Each is CRAOr N; r is a 5 or 6 membered carbocyclic or heterocyclic ring which may be further fused or substituted; and (1) when ring B is a non-fused 6-membered ring, X1And X2Is N, and X3Is C; and (2) when ring B is a fused 6-membered ring, ring B has formula II
Figure 2
The structure of (1). In this configuration, the wavy line indicates the point of attachment to ring a; q1To Q6Each is C or N; and when the limitation (2) applies, (I) X1、X2And X3Is N; or (II) R is two or more fused or non-fused 5 or 6 membered carbocyclic or heterocyclic rings, or (III) both.

Description

Organic electroluminescent material and device
CROSS-REFERENCE TO RELATED APPLICATIONS
Priority of the present application for united states provisional application No. 62/906,305 filed on 26/9/2019 and united states provisional application No. 63/010,815 filed on 16/4/2020, as required by 35u.s.c. 119(e), the entire contents of which are incorporated herein by reference.
Technical Field
The present disclosure relates generally to organometallic compounds and formulations and various uses thereof, including as emitters in devices such as organic light emitting diodes and related electronic devices.
Background
Photovoltaic devices utilizing organic materials are becoming increasingly popular for a variety of reasons. Many of the materials used to make such devices are relatively inexpensive, and therefore organic photovoltaic devices have the potential for cost advantages over inorganic devices. In addition, the inherent properties of organic materials (e.g., their flexibility) may make them more suitable for particular applications, such as fabrication on flexible substrates. Examples of organic optoelectronic devices include organic light emitting diodes/devices (OLEDs), organic phototransistors, organic photovoltaic cells, and organic photodetectors. For OLEDs, organic materials may have performance advantages over conventional materials.
OLEDs utilize organic thin films that emit light when a voltage is applied across the device. OLEDs are becoming an increasingly interesting technology for applications such as flat panel displays, lighting and backlighting.
One application of phosphorescent emissive molecules is in full color displays. Industry standards for such displays require pixels adapted to emit a particular color, known as a "saturated" color. In particular, these standards require saturated red, green, and blue pixels. Alternatively, OLEDs can be designed to emit white light. In conventional liquid crystal displays, an absorptive filter is used to filter the emission from a white backlight to produce red, green, and blue emissions. The same technique can also be used for OLEDs. The white OLED may be a single emission layer (EML) device or a stacked structure. Color can be measured using CIE coordinates well known in the art.
Disclosure of Invention
In one aspect, the present disclosure provides a composition comprising formula I
Figure BDA0002705770930000021
First ligand L ofAThe compound of (1). In formula I:
ring B is a 5-or 6-membered carbocyclic or heterocyclic ring, which may be further fused;
X1、X2and X3Each independently is CRAOr N;
r is a 5 or 6 membered carbocyclic or heterocyclic ring which may be further fused or substituted;
with the proviso that
(1) When ring B is a non-fused 6-membered ring, X1And X2Is N, and X3Is C;
(2) when ring B is a fused 6-membered ring, ring B has the following structure of formula II,
Figure BDA0002705770930000022
wherein:
the wavy line indicates the point of connection to ring a;
Q1、Q2、Q3、Q4、Q5and Q6Each independently is C or N;and is
When the restriction condition (2) applies, at least one of the following conditions is true:
(I)X1、X2and X3Is N; or
(II) R is two or more fused or non-fused 5-or 6-membered carbocyclic or heterocyclic rings which may be further fused or substituted;
RBand RCEach independently represents a single to a maximum number of permissible substitutions, or no substitution;
each RA、RBAnd RCIndependently hydrogen or a substituent selected from the group consisting of the general substituents disclosed herein, and combinations thereof;
LAcoordination to metal M via a designated dotted line;
m is selected from the group consisting of: ir, Os, Pt, Pd, Cu, Ag and Au;
m may coordinate to other ligands;
LAcan be joined with other ligands to form tridentate, tetradentate, pentadentate, or hexadentate ligands; and is
Any two substituents may be joined or fused to form a ring.
In another aspect, the present disclosure provides a formulation of a compound of the present disclosure.
In yet another aspect, the present disclosure provides an OLED having an organic layer comprising a compound of the present disclosure.
In yet another aspect, the present disclosure provides a consumer product comprising an OLED having an organic layer comprising a compound of the present disclosure.
Drawings
Fig. 1 shows an organic light emitting device.
Fig. 2 shows an inverted organic light emitting device without a separate electron transport layer.
Detailed Description
A. Term(s) for
Unless otherwise specified, the following terms as used herein are defined as follows:
as used herein, the term "organic" includes polymeric materials and small molecule organic materials that may be used to fabricate organic optoelectronic devices. "Small molecule" refers to any organic material that is not a polymer, and "small molecules" may actually be quite large. In some cases, the small molecule may include a repeat unit. For example, the use of long chain alkyl groups as substituents does not remove a molecule from the "small molecule" class. Small molecules can also be incorporated into polymers, for example as pendant groups on the polymer backbone or as part of the backbone. Small molecules can also serve as the core moiety of a dendrimer, which consists of a series of chemical shells built on the core moiety. The core moiety of the dendrimer may be a fluorescent or phosphorescent small molecule emitter. Dendrimers can be "small molecules," and all dendrimers currently used in the OLED art are considered small molecules.
As used herein, "top" means furthest from the substrate, and "bottom" means closest to the substrate. Where a first layer is described as being "disposed" over "a second layer, the first layer is disposed farther from the substrate. Other layers may be present between the first and second layers, unless it is specified that the first layer is "in contact with" the second layer. For example, a cathode may be described as "disposed over" an anode even though various organic layers are present between the cathode and the anode.
As used herein, "solution processable" means capable of being dissolved, dispersed or transported in and/or deposited from a liquid medium in the form of a solution or suspension.
A ligand may be referred to as "photoactive" when it is believed that the ligand contributes directly to the photoactive properties of the emissive material. A ligand may be referred to as "ancillary" when it is believed that the ligand does not contribute to the photoactive properties of the emissive material, but the ancillary ligand may alter the properties of the photoactive ligand.
As used herein, and as will be generally understood by those skilled in the art, if the first energy level is closer to the vacuum energy level, the first "Highest Occupied Molecular Orbital" (HOMO) or "Lowest Unoccupied Molecular Orbital" (LUMO) energy level is "greater than" or "higher than" the second HOMO or LUMO energy level. Since Ionization Potential (IP) is measured as negative energy relative to vacuum level, a higher HOMO level corresponds to an IP with a smaller absolute value (less negative IP). Similarly, a higher LUMO energy level corresponds to an Electron Affinity (EA) with a smaller absolute value (a less negative EA). On a conventional energy level diagram with vacuum levels at the top, the LUMO energy level of a material is higher than the HOMO energy level of the same material. The "higher" HOMO or LUMO energy level appears closer to the top of this figure than the "lower" HOMO or LUMO energy level.
As used herein, and as will be generally understood by those skilled in the art, a first work function is "greater than" or "higher than" a second work function if the first work function has a higher absolute value. Since the work function is typically measured as negative relative to the vacuum level, this means that the "higher" work function is more negative (more negative). On a conventional energy level diagram with vacuum level at the top, the "higher" work function is illustrated as being farther from the vacuum level in the downward direction. Thus, the definitions of HOMO and LUMO energy levels follow a different rule than work functions.
The terms "halo," "halogen," and "halo" are used interchangeably and refer to fluorine, chlorine, bromine, and iodine.
The term "acyl" refers to a substituted carbonyl group (C (O) -Rs)。
The term "ester" refers to a substituted oxycarbonyl group (-O-C (O) -R)sor-C (O) -O-Rs) A group.
The term "ether" means-ORsA group.
The terms "thio" or "thioether" are used interchangeably and refer to-SRsA group.
The term "sulfinyl" refers to-S (O) -RsA group.
The term "sulfonyl" refers to-SO2-RsA group.
The term "phosphino" refers to-P (R)s)3Group of eachR issMay be the same or different.
The term "silyl" refers to-Si (R)s)3Group, wherein each RsMay be the same or different.
The term "oxyboronyl" refers to-B (R)s)2Group or Lewis adduct thereof (R) -B (R)s)3Group, wherein RsMay be the same or different.
In each of the above, RsMay be hydrogen or a substituent selected from the group consisting of: deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, aralkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, and combinations thereof. Preferred RsSelected from the group consisting of: alkyl, cycloalkyl, aryl, heteroaryl, and combinations thereof.
The term "alkyl" refers to and includes straight and branched chain alkyl groups. Preferred alkyl groups are those containing from one to fifteen carbon atoms and include methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1-dimethylpropyl, 1, 2-dimethylpropyl, 2-dimethylpropyl, and the like. In addition, the alkyl group may be optionally substituted.
The term "cycloalkyl" refers to and includes monocyclic, polycyclic and spiroalkyl groups. Preferred cycloalkyl groups are those containing 3 to 12 ring carbon atoms and include cyclopropyl, cyclopentyl, cyclohexyl, bicyclo [3.1.1] heptyl, spiro [4.5] decyl, spiro [5.5] undecyl, adamantyl, and the like. In addition, the cycloalkyl group may be optionally substituted.
The term "heteroalkyl" or "heterocycloalkyl" refers to an alkyl or cycloalkyl group, respectively, having at least one carbon atom replaced with a heteroatom. Optionally, the at least one heteroatom is selected from O, S, N, P, B, Si and Se, preferably O, S or N. In addition, heteroalkyl or heterocycloalkyl groups may be optionally substituted.
The term "alkenyl" refers to and includes straight and branched chain alkenyl groups. An alkenyl group is essentially an alkyl group that includes at least one carbon-carbon double bond in the alkyl chain. Cycloalkenyl is essentially cycloalkyl that includes at least one carbon-carbon double bond in the cycloalkyl ring. The term "heteroalkenyl" as used herein refers to an alkenyl group having at least one carbon atom replaced with a heteroatom. Optionally, the at least one heteroatom is selected from O, S, N, P, B, Si and Se, preferably O, S or N. Preferred alkenyl, cycloalkenyl or heteroalkenyl groups are those containing from two to fifteen carbon atoms. In addition, the alkenyl, cycloalkenyl or heteroalkenyl groups may be optionally substituted.
The term "alkynyl" refers to and includes straight and branched chain alkynyl groups. Alkynyl is essentially an alkyl group comprising at least one carbon-carbon triple bond in the alkyl chain. Preferred alkynyl groups are those containing from two to fifteen carbon atoms. In addition, alkynyl groups may be optionally substituted.
The terms "aralkyl" or "arylalkyl" are used interchangeably and refer to an alkyl group substituted with an aryl group. In addition, the aralkyl group may be optionally substituted.
The term "heterocyclyl" refers to and includes both aromatic and non-aromatic cyclic groups containing at least one heteroatom. Optionally, the at least one heteroatom is selected from O, S, N, P, B, Si and Se, preferably O, S or N. Aromatic heterocyclic groups may be used interchangeably with heteroaryl groups. Preferred non-aromatic heterocyclic groups are heterocyclic groups containing 3 to 7 ring atoms including at least one heteroatom and include cyclic amines such as morpholinyl, piperidinyl, pyrrolidinyl and the like, and cyclic ethers/thioethers such as tetrahydrofuran, tetrahydropyran, tetrahydrothiophene and the like. In addition, the heterocyclic group may be optionally substituted.
The term "aryl" refers to and includes monocyclic aromatic hydrocarbon radicals and polycyclic aromatic ring systems. Polycyclic rings can have two or more rings in which two carbons are common to two adjoining rings (the rings are "fused"), wherein at least one of the rings is an aromatic hydrocarbyl, e.g., the other rings can be cycloalkyls, cycloalkenyls, aryls, heterocyclics, and/or heteroaryls. Preferred aryl groups are those containing from six to thirty carbon atoms, preferably from six to twenty carbon atoms, more preferably from six to twelve carbon atoms. Particularly preferred is a carbon material having six carbons and ten carbonsCarbon or twelve carbon aryl. Suitable aryl groups include phenyl, biphenyl, terphenyl, triphenylene, tetraphenylene, naphthalene, anthracene, phenalene, phenanthrene, fluorene, pyrene, perylene,
Figure BDA0002705770930000051
Perylene and azulene, preferably phenyl, biphenyl, terphenyl, triphenylene, fluorene and naphthalene. In addition, the aryl group may be optionally substituted.
The term "heteroaryl" refers to and includes monocyclic aromatic groups and polycyclic aromatic ring systems that include at least one heteroatom. Heteroatoms include, but are not limited to O, S, N, P, B, Si and Se. In many cases O, S or N are preferred heteroatoms. Monocyclic heteroaromatic systems are preferably monocyclic with 5 or 6 ring atoms, and rings may have one to six heteroatoms. A heteropolycyclic system can have two or more rings in which two atoms are common to two adjoining rings (the rings are "fused"), wherein at least one of the rings is heteroaryl, e.g., the other rings can be cycloalkyls, cycloalkenyls, aryls, heterocycles and/or heteroaryls. The heterocyclic aromatic ring system may have one to six heteroatoms per ring of the polycyclic aromatic ring system. Preferred heteroaryl groups are those containing from three to thirty carbon atoms, preferably from three to twenty carbon atoms, more preferably from three to twelve carbon atoms. Suitable heteroaryl groups include dibenzothiophene, dibenzofuran, dibenzoselenophene, furan, thiophene, benzofuran, benzothiophene, benzoselenophene, carbazole, indolocarbazole, pyridylindole, pyrrolobipyridine, pyrazole, imidazole, triazole, oxazole, thiazole, oxadiazole, oxatriazole, dioxazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, triazine, oxazine, oxathiazine, oxadiazine, indole, benzimidazole, indazole, indolizine, benzoxazole, benzisoxazole, benzothiazole, quinoline, isoquinoline, quinazoline, quinoxaline, naphthyridine, phthalazine, pteridine, xanthene, acridine, phenazine, phenothiazine, phenoxazine, benzofuropyridine, furobipyridine, benzothienopyridine, thienobipyridine, benzothienopyridine, and selenenopyridine, preferably dibenzothiophene, and benzothiophene, Dibenzofurans, dibenzoselenophenes, carbazoles, indolocarbazoles, imidazoles, pyridines, triazines, benzimidazoles, 1, 2-azaborines, 1, 3-azaborines, 1, 4-azaborines, borazines, and aza analogs thereof. In addition, the heteroaryl group may be optionally substituted.
Of the aryl and heteroaryl groups listed above, triphenylene, naphthalene, anthracene, dibenzothiophene, dibenzofuran, dibenzoselenophene, carbazole, indolocarbazole, imidazole, pyridine, pyrazine, pyrimidine, triazine, and benzimidazole are of particular interest, as well as their respective corresponding aza analogues.
The terms alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aralkyl, heterocyclyl, aryl, and heteroaryl, as used herein, are independently unsubstituted or independently substituted with one or more general substituents.
In many cases, typical substituents are selected from the group consisting of: deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, aralkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphino, borinyl, and combinations thereof.
In some cases, preferred general substituents are selected from the group consisting of: deuterium, fluorine, alkyl, cycloalkyl, heteroalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, aryl, heteroaryl, nitrile, isonitrile, thio, oxyboronyl, and combinations thereof.
In some cases, more preferred general substituents are selected from the group consisting of: deuterium, fluorine, alkyl, cycloalkyl, alkoxy, aryloxy, amino, silyl, oxyboronyl, aryl, heteroaryl, thio, and combinations thereof.
In other cases, most preferred general substituents are selected from the group consisting of: deuterium, fluoro, alkyl, cycloalkyl, aryl, heteroaryl, and combinations thereof.
The terms "substituted" and "substitution" mean that a substituent other than H is bonded toRelevant positions, such as carbon or nitrogen. For example, when R is1When representing a single substitution, then one R1Must not be H (i.e., substituted). Similarly, when R is1When representing disubstituted, then two R1Must not be H. Similarly, when R is1When represents zero or no substitution, R1For example, it may be hydrogen of available valency for the ring atoms, such as the carbon atom of benzene and the nitrogen atom of pyrrole, or it may be hydrogen of only zero for ring atoms having fully saturated valency, such as the nitrogen atom of pyridine. The maximum number of substitutions possible in a ring structure will depend on the total number of available valences in the ring atoms.
As used herein, "a combination thereof" means that one or more members of the applicable list are combined to form a known or chemically stable arrangement that one of ordinary skill in the art can envision from the applicable list. For example, alkyl and deuterium can be combined to form a partially or fully deuterated alkyl; halogen and alkyl may combine to form haloalkyl substituents; and halogen, alkyl, and aryl groups may be combined to form haloaralkyl groups. In one example, the term substituted includes combinations of two to four of the listed groups. In another example, the term substitution includes a combination of two to three groups. In yet another example, the term substitution includes a combination of two groups. Preferred combinations of substituents are those containing up to fifty atoms other than hydrogen or deuterium, or those containing up to forty atoms other than hydrogen or deuterium, or those containing up to thirty atoms other than hydrogen or deuterium. In many cases, a preferred combination of substituents will include up to twenty atoms that are not hydrogen or deuterium.
The term "aza" in the fragment described herein, i.e., aza-dibenzofuran, aza-dibenzothiophene, etc., means that one or more of the C-H groups in the corresponding aromatic ring can be replaced by a nitrogen atom, for example and without any limitation, azatriphenylene encompasses dibenzo [ f, H ] quinoxaline and dibenzo [ f, H ] quinoline. Other nitrogen analogs of the aza-derivatives described above can be readily envisioned by one of ordinary skill in the art, and all such analogs are intended to be encompassed by the term as set forth herein.
As used herein, "deuterium" refers to an isotope of hydrogen. Deuterated compounds can be readily prepared using methods known in the art. For example, U.S. patent No. 8,557,400, patent publication No. WO 2006/095951, and U.S. patent application publication No. US 2011/0037057 (which are incorporated herein by reference in their entirety) describe the preparation of deuterium substituted organometallic complexes. With further reference to \37154min (Ming Yan) et al, Tetrahedron (Tetrahedron)2015,71,1425-30 and azrote (Atzrodt) et al, german applied chemistry (angelw. chem. int. ed.) (review) 2007,46,7744-65, which are incorporated by reference in their entirety, describe efficient routes for deuteration of methylene hydrogens in benzylamines and replacement of aromatic ring hydrogens with deuterium, respectively.
It is understood that when a molecular fragment is described as a substituent or otherwise attached to another moiety, its name can be written as if it were a fragment (e.g., phenyl, phenylene, naphthyl, dibenzofuranyl) or as if it were an entire molecule (e.g., benzene, naphthalene, dibenzofuran). As used herein, these different named substituents or the manner of linking the fragments are considered equivalent.
In some cases, a pair of adjacent substituents may optionally join or be fused to form a ring. Preferred rings are five-, six-or seven-membered carbocyclic or heterocyclic rings, including both cases where a portion of the ring formed by the pair of substituents is saturated and where a portion of the ring formed by the pair of substituents is unsaturated. As used herein, "adjacent" means that the two substituents involved can be on the same ring next to each other, or on two adjacent rings having two nearest available substitutable positions (e.g., the 2, 2' positions in biphenyl or the 1, 8 positions in naphthalene), so long as they can form a stable fused ring system.
B. Compounds of the present disclosure
In one aspect, the present disclosure provides a composition comprising formula I
Figure BDA0002705770930000081
First ligand L ofAThe compound of (1). In formula I:
ring B is a 5-or 6-membered carbocyclic or heterocyclic ring, which may be further fused;
X1、X2and X3Each independently is CRAOr N;
r is a 5 or 6 membered carbocyclic or heterocyclic ring which may be further fused or substituted;
with the proviso that
(1) When ring B is a non-fused 6-membered ring, X1And X2Is N, and X3Is C;
(2) when ring B is a fused 6-membered ring, ring B has formula II
Figure BDA0002705770930000082
The structure of (1);
wherein:
the wavy line indicates the point of connection to ring a;
Q1、Q2、Q3、Q4、Q5and Q6Each independently is C or N; and is
When the restriction condition (2) applies, at least one of the following conditions is true:
(I)X1、X2and X3Is N; or
(II) R is two or more fused or non-fused 5-or 6-membered carbocyclic or heterocyclic rings which may be further fused or substituted;
RBand RCEach independently represents a single to a maximum number of permissible substitutions, or no substitution;
each RA、RBAnd RCIndependently hydrogen or a substituent selected from the group consisting of the general substituents disclosed herein, and combinations thereof;
LAcoordination to metal M via a designated dotted line;
m is selected from the group consisting of: ir, Os, Pt, Pd, Cu, Ag and Au;
m may coordinate to other ligands;
LAcan be joined with other ligands to form tridentate, tetradentate, pentadentate, or hexadentate ligands; and is
Any two substituents may be joined or fused to form a ring.
In some embodiments, each R isA、RBAnd RCIndependently hydrogen or a substituent selected from the group consisting of the preferred general substituents disclosed herein, and combinations thereof. In some embodiments, each R isA、RBAnd RCIndependently hydrogen or a substituent selected from the group consisting of the more preferred generic substituents disclosed herein, and combinations thereof.
In some embodiments, M is Ir. In some embodiments, M is Pt.
In some embodiments, X1And X2Is N, and X3Is C. In some embodiments, X1Is N, and X2And X3Is C. In some embodiments, X1And X3Is N, and X2Is C. In some embodiments, X1And X3Is C, and X2Is N.
In some embodiments, R is a substituted or unsubstituted 6-membered aromatic or heteroaromatic ring. In some embodiments, R is a substituted or unsubstituted 5-membered heteroaryl ring.
In some embodiments, R is a substituted or unsubstituted cyclohexyl ring. In some embodiments, R is a substituted or unsubstituted cyclopentyl ring. In some embodiments, R is selected from the group consisting of: imidazole, oxazole, thiazole, pyridine, phenyl, biphenyl, carbazole, benzofuran, benzothiophene, dibenzofuran, and dibenzothiophene.
In some embodiments, R is two or more fused 5-or 6-membered carbocyclic or heterocyclic rings, which may be further fused or substituted. In some embodiments, R is two or more non-fused 5-or 6-membered carbocyclic or heterocyclic rings, which may be further substituted. In some embodiments, R is two or more fused 5-or 6-membered aromatic or heteroaromatic rings, which may be further fused or substituted. In some embodiments, R is two or more non-fused 5-or 6-membered aromatic or heteroaromatic rings, which may be further substituted.
In some embodiments, ring B hasHaving the structure of formula II, and Q1、Q2、Q3、Q4、Q5And Q6Each of which is C. In some embodiments, ring B has the structure of formula II, and Q1、Q2、Q3、Q4、Q5And Q6Each of which is N.
In some embodiments, ring B is selected from the group consisting of: phenyl, pyridine, pyrazine, pyridazine, pyrimidine, triazine, furan, thiophene, pyrrole, imidazole, oxazole, and thiazole. In some embodiments, ring B is a 5-membered ring. In some embodiments, ring B is a fused 5-membered ring.
In some embodiments, the compound comprises at least one substituted or unsubstituted phenyl-pyridine ligand. In some embodiments, the compound comprises at least one substituted or unsubstituted acetyl-pyruvate ligand.
In some embodiments, the compound is compounded. In some embodiments, the compounds are homoleptic. In some embodiments, the compound is neutral.
In some embodiments, LAHaving a structure selected from the group consisting of:
Figure BDA0002705770930000101
in some embodiments, ring B has a structure selected from the group consisting of:
Figure BDA0002705770930000102
wherein n is an integer from 1 to 480, and for each n, the substituent R is selected as followsD、RE、RFAnd RG
Figure BDA0002705770930000103
Figure BDA0002705770930000111
Figure BDA0002705770930000121
Figure BDA0002705770930000131
Figure BDA0002705770930000141
Figure BDA0002705770930000151
Wherein R is1To R30Has the following structure:
Figure BDA0002705770930000161
Figure BDA0002705770930000162
in some embodiments, R in formula I has a structure selected from the group consisting of:
Figure BDA0002705770930000163
Figure BDA0002705770930000164
Figure BDA0002705770930000171
Figure BDA0002705770930000172
which can advance oneStep (2) is replaced;
wherein:
each Y is independently selected from the group consisting of: s, O, NRCy1、CRCy2RCy3And SiRCy4RCy5
Each Q is independently CRCyOr N; and is
RCy、RCy1、RCy2、RCy3、RCy4And RCy5Each of which is independently hydrogen or a substituent selected from the group consisting of: deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, oxyboronyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphino, and combinations thereof.
In some embodiments, X1、X2And X3Is N, and R has the structure
Figure BDA0002705770930000181
In some such embodiments, RCySelected from the group consisting of: halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, aryl, heteroaryl, partially or fully deuterated versions thereof, partially or fully fluorinated versions thereof, and combinations thereof.
In some embodiments, ligand LAIs selected from L defined asA1-1To LA3600-344The group consisting of:
Figure BDA0002705770930000182
Figure BDA0002705770930000191
Figure BDA0002705770930000201
Figure BDA0002705770930000211
Figure BDA0002705770930000221
Figure BDA0002705770930000231
Figure BDA0002705770930000241
Figure BDA0002705770930000251
Figure BDA0002705770930000261
Figure BDA0002705770930000271
Figure BDA0002705770930000281
Figure BDA0002705770930000291
Figure BDA0002705770930000301
Figure BDA0002705770930000311
Figure BDA0002705770930000321
Figure BDA0002705770930000331
Figure BDA0002705770930000341
Figure BDA0002705770930000351
Figure BDA0002705770930000361
Figure BDA0002705770930000371
Figure BDA0002705770930000381
wherein i is an integer from 1 to 3600, and for each LAi-m,RH、RIAnd G is defined as follows:
Figure BDA0002705770930000382
Figure BDA0002705770930000391
Figure BDA0002705770930000401
Figure BDA0002705770930000411
Figure BDA0002705770930000421
Figure BDA0002705770930000431
Figure BDA0002705770930000441
Figure BDA0002705770930000451
Figure BDA0002705770930000461
Figure BDA0002705770930000471
Figure BDA0002705770930000481
Figure BDA0002705770930000491
Figure BDA0002705770930000501
Figure BDA0002705770930000511
Figure BDA0002705770930000521
Figure BDA0002705770930000531
Figure BDA0002705770930000541
Figure BDA0002705770930000551
Figure BDA0002705770930000561
Figure BDA0002705770930000571
Figure BDA0002705770930000581
Figure BDA0002705770930000591
Figure BDA0002705770930000601
Figure BDA0002705770930000611
Figure BDA0002705770930000621
Figure BDA0002705770930000631
wherein R isH1To RH30Has the following structure:
Figure BDA0002705770930000632
Figure BDA0002705770930000633
Figure BDA0002705770930000641
and is
Wherein G is1To G20Has the following structure:
Figure BDA0002705770930000642
Figure BDA0002705770930000643
in some embodiments, the compound is of formula M (L)A)p(LB)q(LC)rWherein L isBAnd LCEach is a bidentate ligand; and wherein p is 1,2 or 3, q is 0, 1 or 2, r is 0, 1 or 2, and p + q + r is the oxidation state of the metal M. In some such embodiments, the compound has a formula selected from the group consisting of: ir (L)A)3、Ir(LA)(LB)2、Ir(LA)2(LB)、Ir(LA)2(LC) And Ir (L)A)(LB)(LC) (ii) a And wherein LA、LBAnd LCAre different from each other.
In some embodiments, LBAnd LCEach independently selected from the group consisting of:
Figure BDA0002705770930000651
Figure BDA0002705770930000652
Figure BDA0002705770930000661
wherein:
Y1to Y13Each of which is independently selected from the group consisting of C and N;
y' is selected from the group consisting of: BR (BR)e、NRe、PRe、O、S、Se、C=O、S=O、SO2、CReRf、SiReRfAnd GeReRf
ReAnd RfMay be fused or joined to form a ring;
each Ra、Rb、RcAnd RdIndependently represent the allowed replacements of zero, single, or up to the maximum number of their associated rings;
Ra1、Rb1、Rc1、Ra、Rb、Rc、Rd、Reand RfEach of which is independently hydrogen or a substituent selected from the group consisting of the general substituents defined herein; and is
Ra、Rb、RcAnd RdTwo adjacent substituents of (a) may be fused or joined to form a ring or form a multidentate ligand.
In some embodiments, LBAnd LCEach independently selected from the group consisting of:
Figure BDA0002705770930000662
Figure BDA0002705770930000671
Figure BDA0002705770930000681
Figure BDA0002705770930000691
wherein:
Ra'、Rb' and Rc' each independently represents zero, single, or up to the maximum number of allowed substitutions of its associated ring;
Ra、Rb、Rc、RN、Ra'、Rb' and RcEach of' is independently hydrogen or a substituent selected from the group consisting of the general substituents defined herein; and is
Ra'、Rb' and RcTwo adjacent substituents of' may be fused or joined to form a ring or form a multidentate ligand.
In some embodiments, LBSelected from the group consisting of compounds having the general formula LBkL of (k is 1 to 264)B1To LB264The group consisting of:
Figure BDA0002705770930000692
Figure BDA0002705770930000701
Figure BDA0002705770930000711
Figure BDA0002705770930000721
Figure BDA0002705770930000731
Figure BDA0002705770930000741
Figure BDA0002705770930000751
Figure BDA0002705770930000761
Figure BDA0002705770930000771
in some embodiments, LCSelected from the group consisting of: has a formula based on
Figure BDA0002705770930000772
L of the structureCj-I(ii) a And
has a formula based on
Figure BDA0002705770930000773
L of the structureCj-IIWherein j is an integer from 1 to 1416, wherein for LCj-IAnd LCj-IIEach L inCj,R201And R202Each independently defined as follows:
Figure BDA0002705770930000774
Figure BDA0002705770930000781
Figure BDA0002705770930000791
Figure BDA0002705770930000801
Figure BDA0002705770930000811
Figure BDA0002705770930000821
Figure BDA0002705770930000831
Figure BDA0002705770930000841
Figure BDA0002705770930000851
wherein R isD1To RD246Has the following structure:
Figure BDA0002705770930000852
Figure BDA0002705770930000861
Figure BDA0002705770930000871
Figure BDA0002705770930000881
Figure BDA0002705770930000891
in some embodiments, the compound has the formula Ir (L)Ai-m)(LBk)2Or formula Ir (L)Ai-m)2(LBk) Which only corresponds to LBkThose compounds of ligands which correspond to the following structures: l isB1、LB2、LB18、LB28、LB38、LB108、LB118、LB122、LB124、LB126、LB128、LB130、LB32、LB134、LB136、LB138、LB140、LB142、LB144、LB156、LB58、LB160、LB162、LB164、LB168、LB172、LB175、LB204、LB206、LB214、LB216、LB218、LB220、LB222、LB231、LB233、LB235、LB237、LB240、LB242、LB244、LB246、LB248、LB250、LB252、LB254、LB256、LB258、LB260、LB262、LB263And LB264
In some embodiments, the compound has the formula Ir (L)Ai-m)(LBk)2Or formula Ir (L)Ai-m)2(LBk) Which only corresponds to LBkThose compounds of ligands which correspond to the following structures: l isB1、LB2、LB18、LB28、LB38、LB108、LB118、LB122、LB124、LB126、LB128、LB132、LB136、LB138、LB142、LB156、LB162、LB204、LB206、LB214、LB216、LB218、LB220、LB231、LB233、LB237And LB264
In some embodiments, the compound has the formula Ir (L)Ai-m)2(LCj-I) Or formula Ir (L)Ai-m)2(LCj-II) Which only corresponds to LCj-IAnd LCj-IIThose compounds of ligands, corresponding to R1' and R2' is defined as one of the following structures: rD1、RD3、RD4、RD5、RD9、RD10、RD17、RD18、RD20、RD22、RD37、RD40、RD41、RD42、RD43、RD48、RD49、RD50、RD54、RD55、RD58、RD59、RD78、RD79、RD81、RD87、RD88、RD89、RD93、RD116、RD117、RD118、RD119、RD120、RD133、RD134、RD135、RD136、RD143、RD144、RD145、RD146、RD147、RD149、RD151、RD154、RD155、RD156、RD161、RD175、RD190、RD193、RD200、RD201、RD206、RD210、RD214、RD215、RD216、RD218、RD219、RD220、RD227、RD237、RD241、RD242、RD245And RD246
In some embodiments, the compound has the formula Ir (L)Ai-m)2(LCj-I) Or formula Ir (L)Ai-m)2(LCj-II) Which only corresponds to LCj-IAnd LCj-IIThose compounds of ligands, corresponding to R1' and R2' is defined as one of the following structures: rD1、RD3、RD4、RD5、RD9、RD17、RD22、RD43、RD50、RD78、RD116、RD118、RD133、RD134、RD135、RD136、RD143、RD144、RD145、RD146、RD149、RD151、RD154、RD155、RD156、RD190、RD193、RD200、RD214、RD218、RD220、RD241And RD245
In some embodiments, the compound has the formula Ir (L)Ai-m)2(LCj-I) Which only corresponds to LCj-IThose compounds of ligands which correspond to the following structures:
Figure BDA0002705770930000901
Figure BDA0002705770930000902
Figure BDA0002705770930000911
Figure BDA0002705770930000921
in some embodiments, the compound has the formula Ir (L)Ai-m)3Wherein i is an integer from 1 to 3600; m is an integer from 1 to 344; and the compound is selected from the group consisting of Ir (L)A1-1)3To Ir (L)A3600-344)3A group of compounds; the compound has the formula Ir: (LAi-m)(LBk)2Wherein i is an integer from 1 to 3600; m is an integer from 1 to 344; k is an integer from 1 to 264; and the compound is selected from the group consisting of Ir (L)A1-1)(LB1)2To Ir (L)A3600-344)(LB264)2A group of compounds; the compound has the formula Ir (L)Ai-m)2(LBk) Wherein i is an integer from 1 to 3600; m is an integer from 1 to 344; k is an integer from 1 to 264; and the compound is selected from the group consisting of Ir (L)A1-1)2(LB1) To Ir (L)A3600-344)2(LB264) A group of compounds; and the compound has the formula Ir (L)Ai-m)2(LCj-I) Or Ir (L)Ai-m)2(LCj-II) Wherein i is an integer from 1 to 3600; m is an integer from 1 to 344; j is an integer from 1 to 1416; and the compound is selected from the group consisting of Ir (L)A1-1)2(LC1-I) To Ir (L)A3600-344)2(LC1416-I) And Ir (L)A1-1)2(LC1-II) To Ir (L)A3600-344)2(LC1416-II) A group of combinations thereof.
In some embodiments, the compound is selected from the group consisting of:
Figure BDA0002705770930000922
Figure BDA0002705770930000931
Figure BDA0002705770930000941
Figure BDA0002705770930000951
Figure BDA0002705770930000961
C. OLEDs and devices of the present disclosure
In another aspect, the present disclosure also provides an OLED device comprising a first organic layer comprising a compound as disclosed in the above compounds section of the present disclosure.
In some embodiments, the OLED comprises an anode, a cathode, and a first organic layer disposed between the anode and the cathode. The first organic layer may comprise a material comprising formula I
Figure BDA0002705770930000971
First ligand L ofAThe compound of (1). In formula I:
ring B is a 5-or 6-membered carbocyclic or heterocyclic ring, which may be further fused;
X1、X2and X3Each independently is CRAOr N;
r is a 5 or 6 membered carbocyclic or heterocyclic ring which may be further fused or substituted;
with the proviso that
(1) When ring B is a non-fused 6-membered ring, X1And X2Is N, and X3Is C;
(2) when ring B is a fused 6-membered ring, ring B has the following structure of formula II,
Figure BDA0002705770930000972
wherein:
the wavy line indicates the point of connection to ring a;
Q1、Q2、Q3、Q4、Q5and Q6Each independently is C or N; and is
When the restriction condition (2) applies, at least one of the following conditions is true:
(I)X1、X2and X3Is N; or
(II) R is two or more fused or non-fused 5-or 6-membered carbocyclic or heterocyclic rings which may be further fused or substituted;
RBand RCEach independently represents a single to a maximum number of permissible substitutions, or no substitution;
each RA、RBAnd RCIndependently hydrogen or a substituent selected from the group consisting of the general substituents disclosed herein, and combinations thereof;
wherein L isACoordination to metal M via a designated dotted line;
wherein M is selected from the group consisting of: ir, Os, Pt, Pd, Cu, Ag and Au;
wherein M can coordinate to other ligands;
LAcan be joined with other ligands to form tridentate, tetradentate, pentadentate, or hexadentate ligands; and is
Any two substituents may be joined or fused to form a ring.
In some embodiments, the organic layer may be an emissive layer and the compound as described herein may be an emissive dopant or a non-emissive dopant.
In some embodiments, the organic layer may further comprise a host, wherein the host comprises a triphenylene comprising a benzo-fused thiophene or a benzo-fused furan, wherein any substituent in the host is a non-fused substituent independently selected from the group consisting of: cnH2n+1、OCnH2n+1、OAr1、N(CnH2n+1)2、N(Ar1)(Ar2)、CH=CH-CnH2n+1、C≡CCnH2n+1、Ar1、Ar1-Ar2、CnH2n-Ar1Or no substituent, wherein n is 1 to 10; and wherein Ar1And Ar2Independently selected from the group consisting of: benzene, biphenyl, naphthalene, triphenylene, carbazole, and heteroaromatic analogs thereof.
In some embodiments, the organic layer may further comprise a host, wherein the host comprises at least one chemical group selected from the group consisting of: triphenylene, carbazole, indolocarbazole, dibenzothiophene, dibenzofuran, dibenzoselenophene, 5, 9-dioxa-13 b-boronaphtho [3,2,1-de ] anthracene, aza-triphenylene, aza-carbazole, aza-indolocarbazole, aza-dibenzothiophene, aza-dibenzofuran, aza-dibenzoselenophene, and aza- (5, 9-dioxa-13 b-boronaphtho [3,2,1-de ] anthracene).
In some embodiments, the subject may be selected from the group of subjects consisting of:
Figure BDA0002705770930000981
Figure BDA0002705770930000991
Figure BDA0002705770930001001
Figure BDA0002705770930001002
and combinations thereof.
In some embodiments, the organic layer may further comprise a host, wherein the host comprises a metal complex.
In some embodiments, a compound as described herein may be a sensitizer; wherein the device may further comprise a receptor; and wherein the receptor may be selected from the group consisting of: fluorescent emitters, delayed fluorescent emitters, and combinations thereof.
In yet another aspect, the OLEDs of the present disclosure can further comprise an emissive region comprising a compound as disclosed in the above compounds section of the present disclosure.
In some embodiments, the emission area may comprise a material comprising formula I
Figure BDA0002705770930001003
First ligand L ofAThe compound of (1). In formula I:
ring B is a 5-or 6-membered carbocyclic or heterocyclic ring, which may be further fused;
X1、X2and X3Each independently is CRAOr N;
r is a 5 or 6 membered carbocyclic or heterocyclic ring which may be further fused or substituted;
with the proviso that
(1) When ring B is a non-fused 6-membered ring, X1And X2Is N, and X3Is C;
(2) when ring B is a fused 6-membered ring, ring B has the following structure of formula II,
Figure BDA0002705770930001011
wherein:
the wavy line indicates the point of connection to ring a;
Q1、Q2、Q3、Q4、Q5and Q6Each independently is C or N; and is
When the restriction condition (2) applies, at least one of the following conditions is true:
(I)X1、X2and X3Is N; or
(II) R is two or more fused or non-fused 5-or 6-membered carbocyclic or heterocyclic rings which may be further fused or substituted;
RBand RCEach independently represents a single to a maximum number of permissible substitutions, or no substitution;
each RA、RBAnd RCIndependently hydrogen or a substituent selected from the group consisting of the general substituents disclosed herein, and combinations thereof;
wherein L isACoordination to metal M via a designated dotted line;
wherein M is selected from the group consisting of: ir, Os, Pt, Pd, Cu, Ag and Au;
wherein M can coordinate to other ligands;
LAcan be conjugated with other ligands to form trisA dentate, tetradentate, pentadentate or hexadentate ligand; and is
Any two substituents may be joined or fused to form a ring.
In some emissive region embodiments, the compound may be an emissive dopant or a non-emissive dopant. In some emission region embodiments, the emission region comprises a body, wherein the body contains at least one group selected from the group consisting of: metal complexes, triphenylenes, carbazoles, dibenzothiophenes, dibenzofurans, dibenzoselenophenes, aza-triphenylenes, aza-carbazoles, aza-dibenzothiophenes, aza-dibenzofurans, and aza-dibenzoselenophenes.
In some emission area embodiments, the emission area includes a body, wherein the body is selected from the group consisting of the structures listed in the body group defined herein.
In yet another aspect, the present disclosure also provides a consumer product comprising an Organic Light Emitting Device (OLED) having an anode; a cathode; and an organic layer disposed between the anode and the cathode, wherein the organic layer can comprise a compound as disclosed in the above compounds section of the present disclosure.
In some embodiments, the consumer product comprises an OLED having an anode; a cathode; and an organic layer disposed between the anode and the cathode, wherein the organic layer can comprise a material comprising formula I
Figure BDA0002705770930001021
First ligand L ofAThe compound of (1). In formula I:
ring B is a 5-or 6-membered carbocyclic or heterocyclic ring, which may be further fused;
X1、X2and X3Each independently is CRAOr N;
r is a 5 or 6 membered carbocyclic or heterocyclic ring which may be further fused or substituted;
with the proviso that
(1) When ring B is a non-fused 6-membered ring, X1And X2Is N, and X3Is C;
(2) when ring B is a fused 6-membered ring, ring B has the following structure of formula II,
Figure BDA0002705770930001022
wherein:
the wavy line indicates the point of connection to ring a;
Q1、Q2、Q3、Q4、Q5and Q6Each independently is C or N; and is
When the restriction condition (2) applies, at least one of the following conditions is true:
(I)X1、X2and X3Is N; or
(II) R is two or more fused or non-fused 5-or 6-membered carbocyclic or heterocyclic rings which may be further fused or substituted;
RBand RCEach independently represents a single to a maximum number of permissible substitutions, or no substitution;
each RA、RBAnd RCIndependently hydrogen or a substituent selected from the group consisting of the general substituents disclosed herein, and combinations thereof;
wherein L isACoordination to metal M via a designated dotted line;
wherein M is selected from the group consisting of: ir, Os, Pt, Pd, Cu, Ag and Au;
wherein M can coordinate to other ligands;
LAcan be joined with other ligands to form tridentate, tetradentate, pentadentate, or hexadentate ligands; and is
Any two substituents may be joined or fused to form a ring.
In some embodiments, the consumer product may be one of the following: a flat panel display, a computer monitor, a medical monitor, a television, a billboard, a light for interior or exterior lighting and/or signaling, a heads-up display, a fully or partially transparent display, a flexible display, a laser printer, a telephone, a cellular telephone, a tablet, a phablet, a Personal Digital Assistant (PDA), a wearable device, a laptop computer, a digital camera, a video camera, a viewfinder, a microdisplay at a diagonal of less than 2 inches, a 3-D display, a virtual reality or augmented reality display, a vehicle, a video wall containing multiple displays tiled together, a theater or stadium screen, a phototherapy device, and a sign.
Generally, an OLED comprises at least one organic layer disposed between and electrically connected to an anode and a cathode. When current is applied, the anode injects holes and the cathode injects electrons into the organic layer. The injected holes and electrons each migrate toward the oppositely charged electrode. When an electron and a hole are located on the same molecule, an "exciton," which is a localized electron-hole pair with an excited energy state, is formed. When the exciton relaxes by a light emission mechanism, light is emitted. In some cases, the exciton may be localized on an excimer (eximer) or an exciplex. Non-radiative mechanisms (such as thermal relaxation) may also occur, but are generally considered undesirable.
Several OLED materials and configurations are described in U.S. patent nos. 5,844,363, 6,303,238, and 5,707,745, which are incorporated herein by reference in their entirety.
The initial OLEDs used emissive molecules that emit light from a singlet state ("fluorescence"), as disclosed, for example, in U.S. patent No. 4,769,292, which is incorporated by reference in its entirety. Fluorescence emission typically occurs in a time frame of less than 10 nanoseconds.
More recently, OLEDs having emissive materials that emit light from the triplet state ("phosphorescence") have been demonstrated. Baldo et al, "high efficiency Phosphorescent Emission from Organic Electroluminescent Devices" (Nature), 395, 151-154,1998 ("Baldo-I"); and baldo et al, "Very high-efficiency green organic light-emitting devices based on electrophosphorescence (Very high-efficiency green organic light-emitting devices-based on electrophosphorescence)", applied physical promo (appl. phys. lett.), volume 75, stages 3,4-6 (1999) ("baldo-II"), which are incorporated by reference in their entirety. Phosphorescence is described in more detail in U.S. Pat. No. 7,279,704, columns 5-6, which is incorporated by reference.
Fig. 1 shows an organic light emitting device 100. The figures are not necessarily to scale. Device 100 can include substrate 110, anode 115, hole injection layer 120, hole transport layer 125, electron blocking layer 130, emissive layer 135, hole blocking layer 140, electron transport layer 145, electron injection layer 150, protective layer 155, cathode 160, and blocking layer 170. Cathode 160 is a composite cathode having a first conductive layer 162 and a second conductive layer 164. The device 100 may be fabricated by depositing the layers in sequence. The nature and function of these various layers and example materials are described in more detail in U.S. Pat. No. 7,279,704, columns 6-10, which is incorporated by reference.
More instances of each of these layers are available. For example, a flexible and transparent substrate-anode combination is disclosed in U.S. Pat. No. 5,844,363, which is incorporated by reference in its entirety. An example of a p-doped hole transport layer is doped with F at a molar ratio of 50:14TCNQ m-MTDATA as disclosed in U.S. patent application publication No. 2003/0230980, which is incorporated by reference in its entirety. Examples of luminescent and host materials are disclosed in U.S. Pat. No. 6,303,238 to Thompson et al, which is incorporated by reference in its entirety. An example of an n-doped electron transport layer is BPhen doped with Li at a molar ratio of 1:1, as disclosed in U.S. patent application publication No. 2003/0230980, which is incorporated by reference in its entirety. U.S. Pat. Nos. 5,703,436 and 5,707,745, which are incorporated by reference in their entirety, disclose examples of cathodes comprising composite cathodes having a thin layer of a metal (e.g., Mg: Ag) with an overlying transparent, conductive, sputter-deposited ITO layer. The theory and use of barrier layers is described in more detail in U.S. patent No. 6,097,147 and U.S. patent application publication No. 2003/0230980, which are incorporated by reference in their entirety. Examples of injection layers are provided in U.S. patent application publication No. 2004/0174116, which is incorporated by reference in its entirety.A description of the protective layer may be found in U.S. patent application publication No. 2004/0174116, which is incorporated by reference in its entirety.
Fig. 2 shows an inverted OLED 200. The device includes a substrate 210, a cathode 215, an emissive layer 220, a hole transport layer 225, and an anode 230. The device 200 may be fabricated by depositing the layers in sequence. Because the most common OLED configuration has a cathode disposed above an anode, and device 200 has a cathode 215 disposed below an anode 230, device 200 may be referred to as an "inverted" OLED. Materials similar to those described with respect to device 100 may be used in corresponding layers of device 200. Fig. 2 provides one example of how some layers may be omitted from the structure of device 100.
The simple layered structure illustrated in fig. 1 and 2 is provided by way of non-limiting example, and it is to be understood that embodiments of the present disclosure may be used in conjunction with various other structures. The specific materials and structures described are exemplary in nature, and other materials and structures may be used. Functional OLEDs may be obtained by combining the various layers described in different ways, or the layers may be omitted entirely based on design, performance, and cost factors. Other layers not specifically described may also be included. Materials other than those specifically described may be used. Although many of the examples provided herein describe the various layers as comprising a single material, it is understood that combinations of materials may be used, such as mixtures of hosts and dopants, or more generally, mixtures. Further, the layer may have various sub-layers. The names given to the various layers herein are not intended to be strictly limiting. For example, in device 200, hole transport layer 225 transports holes and injects holes into emissive layer 220, and may be described as a hole transport layer or a hole injection layer. In one embodiment, an OLED may be described as having an "organic layer" disposed between a cathode and an anode. This organic layer may comprise a single layer, or may further comprise multiple layers of different organic materials as described, for example, with respect to fig. 1 and 2.
Structures and materials not specifically described may also be used, such as oleds (pleds) comprising polymeric materials, such as disclosed in U.S. patent No. 5,247,190 to frand (Friend), et al, which is incorporated by reference in its entirety. By way of further example, OLEDs having a single organic layer may be used. The OLEDs may be stacked, for example, as described in U.S. patent No. 5,707,745 to forrister (Forrest) et al, which is incorporated by reference in its entirety. The OLED structure may deviate from the simple layered structure illustrated in fig. 1 and 2. For example, the substrate may include an angled reflective surface to improve out-coupling (out-coupling), such as a mesa structure as described in U.S. Pat. No. 6,091,195 to Foster et al, and/or a pit structure as described in U.S. Pat. No. 5,834,893 to Boolean (Bulovic) et al, which are incorporated by reference in their entirety.
Any of the layers of the various embodiments may be deposited by any suitable method, unless otherwise specified. For organic layers, preferred methods include thermal evaporation, ink jetting (as described in U.S. Pat. Nos. 6,013,982 and 6,087,196, both incorporated by reference in their entirety), organic vapor deposition (OVPD) (as described in U.S. Pat. No. 6,337,102 to Foster et al, both incorporated by reference in their entirety), and deposition by Organic Vapor Jet Printing (OVJP) (as described in U.S. Pat. No. 7,431,968, incorporated by reference in its entirety). Other suitable deposition methods include spin coating and other solution-based processes. The solution-based process is preferably carried out in a nitrogen or inert atmosphere. For other layers, a preferred method includes thermal evaporation. Preferred patterning methods include deposition through a mask, cold welding (as described in U.S. Pat. nos. 6,294,398 and 6,468,819, which are incorporated by reference in their entirety), and patterning associated with some of the deposition methods such as inkjet and Organic Vapor Jet Printing (OVJP). Other methods may also be used. The material to be deposited may be modified to suit the particular deposition method. For example, substituents such as alkyl and aryl groups, branched or unbranched, and preferably containing at least 3 carbons, may be used in small molecules to enhance their ability to undergo solution processing. Substituents having 20 carbons or more may be used, and 3 to 20 carbons is a preferred range. A material with an asymmetric structure may have better solution processibility than a material with a symmetric structure because asymmetric materials may have a lower tendency to recrystallize. Dendrimer substituents may be used to enhance the ability of small molecules to undergo solution processing.
Devices fabricated according to embodiments of the present disclosure may further optionally include a barrier layer. One use of barrier layers is to protect the electrodes and organic layers from damage from exposure to hazardous substances in the environment including moisture, vapor, and/or gas. The barrier layer may be deposited on, under or beside the substrate, electrode, or on any other part of the device, including the edge. The barrier layer may comprise a single layer or multiple layers. The barrier layer may be formed by various known chemical vapor deposition techniques and may include compositions having a single phase and compositions having multiple phases. Any suitable material or combination of materials may be used for the barrier layer. The barrier layer may incorporate an inorganic compound or an organic compound or both. Preferred barrier layers comprise a mixture of polymeric and non-polymeric materials as described in U.S. patent No. 7,968,146, PCT patent application nos. PCT/US2007/023098 and PCT/US2009/042829, which are incorporated herein by reference in their entirety. To be considered a "mixture," the aforementioned polymeric and non-polymeric materials that make up the barrier layer should be deposited under the same reaction conditions and/or simultaneously. The weight ratio of polymeric material to non-polymeric material may be in the range of 95:5 to 5: 95. The polymeric material and the non-polymeric material may be produced from the same precursor material. In one example, the mixture of polymeric material and non-polymeric material consists essentially of polymeric silicon and inorganic silicon.
Devices manufactured according to embodiments of the present disclosure may be incorporated into a wide variety of electronic component modules (or units), which may be incorporated into a wide variety of electronic products or intermediate components. Examples of such electronic products or intermediate components include display screens, lighting devices (e.g., discrete light source devices or lighting panels), etc., which may be utilized by end-user product manufacturers. The electronics module may optionally include drive electronics and/or a power source. Devices manufactured in accordance with embodiments of the present disclosure may be incorporated into a wide variety of consumer products having one or more electronic component modules (or units) incorporated therein. A consumer product comprising an OLED comprising a compound of the present disclosure in an organic layer in the OLED is disclosed. The consumer product shall include any kind of product comprising one or more light sources and/or one or more of some type of visual display. Some examples of such consumer products include flat panel displays, curved displays, computer monitors, medical monitors, televisions, billboards, lights for interior or exterior illumination and/or signaling, heads-up displays, fully or partially transparent displays, flexible displays, rollable displays, foldable displays, stretchable displays, laser printers, telephones, cellular telephones, tablet computers, tablet phones, Personal Digital Assistants (PDAs), wearable devices, laptop computers, digital cameras, video cameras, viewfinders, microdisplays (displays less than 2 inches diagonal), 3-D displays, virtual reality or augmented reality displays, vehicles, video walls containing multiple displays tiled together, theater or stadium screens, phototherapy devices, and signs. Various control mechanisms may be used to control devices made in accordance with the present disclosure, including passive matrices and active matrices. Many of the devices are intended to be used in a temperature range that is comfortable for humans, such as 18 ℃ to 30 ℃, and more preferably at room temperature (20-25 ℃), but can be used outside this temperature range (e.g., -40 ℃ to +80 ℃).
More details regarding OLEDs and the definitions described above can be found in U.S. patent No. 7,279,704, which is incorporated herein by reference in its entirety.
The materials and structures described herein may be applied to devices other than OLEDs. For example, other optoelectronic devices such as organic solar cells and organic photodetectors may employ the materials and structures. More generally, organic devices such as organic transistors may employ the materials and structures.
In some embodiments, the OLED has one or more features selected from the group consisting of: flexible, rollable, foldable, stretchable, and bendable. In some embodiments, the OLED is transparent or translucent. In some embodiments, the OLED further comprises a layer comprising carbon nanotubes.
In some embodiments, the OLED further comprises a layer comprising a delayed fluorescence emitter. In some embodiments, the OLED comprises an RGB pixel arrangement or a white plus color filter pixel arrangement. In some embodiments, the OLED is a mobile device, a handheld device, or a wearable device. In some embodiments, the OLED is a display panel having a diagonal of less than 10 inches or an area of less than 50 square inches. In some embodiments, the OLED is a display panel having a diagonal of at least 10 inches or an area of at least 50 square inches. In some embodiments, the OLED is a lighting panel.
In some embodiments, the compound may be an emissive dopant. In some embodiments, the compounds may produce emission via phosphorescence, fluorescence, thermally activated delayed fluorescence (i.e., TADF, also known as E-type delayed fluorescence, see, e.g., U.S. application No. 15/700,352, which is incorporated herein by reference in its entirety), triplet-triplet annihilation, or a combination of these processes. In some embodiments, the emissive dopant may be a racemic mixture, or may be enriched in one enantiomer. In some embodiments, the compounds may be homoleptic (each ligand is the same). In some embodiments, the compounds may be compounded (at least one ligand being different from the others). In some embodiments, when there is more than one ligand that coordinates to the metal, the ligands may all be the same. In some other embodiments, at least one ligand is different from the other ligands. In some embodiments, each ligand may be different from each other. This is also true in embodiments where the ligand that coordinates to the metal can be linked to other ligands that coordinate to the metal to form a tridentate, tetradentate, pentadentate, or hexadentate ligand. Thus, where the coordinating ligands are linked together, in some embodiments all of the ligands may be the same, and in some other embodiments at least one of the linked ligands may be different from the other ligand(s).
In some embodiments, the compounds may be used as phosphorous photosensitizers in OLEDs, where one or more layers in the OLED contain an acceptor in the form of one or more fluorescent and/or delayed fluorescence emitters. In some embodiments, the compounds may be used as a component of an exciplex to be used as a sensitizer. As a phosphosensitizer, the compound must be capable of energy transfer to the acceptor and the acceptor will emit or further transfer energy to the final emitter. The receptor concentration may range from 0.001% to 100%. The acceptor may be in the same layer as the phosphorous sensitizer or in one or more different layers. In some embodiments, the receptor is a TADF emitter. In some embodiments, the acceptor is a fluorescent emitter. In some embodiments, the emission may be produced by any or all of the sensitizer, the receptor, and the final emitter.
According to another aspect, a formulation comprising a compound described herein is also disclosed.
The OLEDs disclosed herein can be incorporated into one or more of consumer products, electronic component modules, and lighting panels. The organic layer may be an emissive layer, and the compound may be an emissive dopant in some embodiments, while the compound may be a non-emissive dopant in other embodiments.
In yet another aspect of the present invention, a formulation comprising the novel compound disclosed herein is described. The formulation may include one or more of the components disclosed herein selected from the group consisting of: a solvent, a host, a hole injection material, a hole transport material, an electron blocking material, a hole blocking material, and an electron transport material.
The present disclosure encompasses any chemical structure comprising the novel compounds of the present disclosure or monovalent or multivalent variants thereof. In other words, the compounds of the present invention or monovalent or multivalent variants thereof may be part of a larger chemical structure. Such chemical structures may be selected from the group consisting of: monomers, polymers, macromolecules and supramolecules (also known as supramolecules). As used herein, "monovalent variant of a compound" refers to a moiety that is the same as a compound but where one hydrogen has been removed and replaced with a bond to the remainder of the chemical structure. As used herein, "multivalent variants of a compound" refers to moieties that are the same as a compound but where more than one hydrogen has been removed and replaced with one or more bonds to the rest of the chemical structure. In the case of supramolecules, the compounds of the invention may also be incorporated into supramolecular complexes without covalent bonds.
D. Combinations of the compounds of the present disclosure with other materials
Materials described herein as suitable for use in a particular layer in an organic light emitting device can be used in combination with a variety of other materials present in the device. For example, the emissive dopants disclosed herein may be used in conjunction with a wide variety of hosts, transport layers, barrier layers, implant layers, electrodes, and other layers that may be present. The materials described or referenced below are non-limiting examples of materials that can be used in combination with the compounds disclosed herein, and one of ordinary skill in the art can readily review the literature to identify other materials that can be used in combination.
a) Conductive dopant:
the charge transport layer may be doped with a conductivity dopant to substantially change its charge carrier density, which in turn will change its conductivity. The conductivity is increased by the generation of charge carriers in the host material and, depending on the type of dopant, a change in the Fermi level of the semiconductor can also be achieved. The hole transport layer may be doped with a p-type conductivity dopant and an n-type conductivity dopant is used in the electron transport layer.
Non-limiting examples of conductivity dopants that can be used in OLEDs in combination with the materials disclosed herein, along with references disclosing those materials, are exemplified below: EP01617493, EP01968131, EP2020694, EP2684932, US20050139810, US20070160905, US20090167167, US2010288362, WO06081780, WO2009003455, WO2009008277, WO2009011327, WO2014009310, US2007252140, US2015060804, US20150123047 and US 2012146012.
Figure BDA0002705770930001081
Figure BDA0002705770930001091
b)HIL/HTL:
The hole injection/transport material used in the present disclosure is not particularly limited, and any compound may be used as long as the compound is generally used as the hole injection/transport material. Examples of materials include (but are not limited to): phthalocyanine or porphyrin derivatives; an aromatic amine derivative; indolocarbazole derivatives; a fluorocarbon-containing polymer; a polymer having a conductive dopant; conductive polymers such as PEDOT/PSS; self-assembling monomers derived from compounds such as phosphonic acids and silane derivatives; metal oxide derivatives, e.g. MoOx(ii) a p-type semiconducting organic compounds, such as 1,4,5,8,9, 12-hexaazatriphenylhexacyano-nitrile; a metal complex; and a crosslinkable compound.
Examples of aromatic amine derivatives for use in HILs or HTLs include, but are not limited to, the following general structures:
Figure BDA0002705770930001092
Ar1to Ar9Each of which is selected from: a group consisting of aromatic hydrocarbon cyclic compounds such as: benzene, biphenyl, terphenyl, triphenylene, naphthalene, anthracene, phenalene, phenanthrene, fluorene, pyrene,
Figure BDA0002705770930001103
Perylene and azulene; a group consisting of aromatic heterocyclic compounds such as: dibenzothiophene, dibenzofuran, dibenzoselenophene, furan, thiophene, benzofuran, benzothiophene, benzoselenophene, carbazole, indolocarbazole, pyridylindole, pyrrolobipyridine, pyrazole, imidazole, triazole, oxazole, thiazole, oxadiazole, oxatriazole, dioxazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, triazineOxazines, oxathiazines, oxadiazines, indoles, benzimidazoles, indazoles, indolizines, benzoxazoles, benzisoxazoles, benzothiazoles, quinolines, isoquinolines, cinnolines, quinazolines, quinoxalines, naphthyridines, phthalazines, pteridines, xanthenes, acridines, phenazines, phenothiazines, phenoxazines, benzofuropyridines, furobipyridines, benzothienopyridines, thienobipyridines, benzoselenenopyridines, and selenophenodipyridines; and a group consisting of 2 to 10 cyclic structural units which are the same type or different types of groups selected from aromatic hydrocarbon ring groups and aromatic heterocyclic groups and are bonded to each other directly or via at least one of an oxygen atom, a nitrogen atom, a sulfur atom, a silicon atom, a phosphorus atom, a boron atom, a chain structural unit and an aliphatic ring group. Each Ar may be unsubstituted or may be substituted with a substituent selected from the group consisting of: deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, aralkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphino, and combinations thereof.
In one aspect, Ar1To Ar9Independently selected from the group consisting of:
Figure BDA0002705770930001101
wherein k is an integer from 1 to 20; x101To X108Is C (including CH) or N; z101Is NAr1O or S; ar (Ar)1Having the same groups as defined above.
Examples of metal complexes used in HILs or HTLs include, but are not limited to, the following general formulas:
Figure BDA0002705770930001102
wherein Met is a metal which may have an atomic weight greater than 40; (Y)101-Y102) Is a bidentate ligand, Y101And Y102Independently selected from C, N, O, P and S; l is101Is an ancillary ligand; k' is an integer value from 1 to the maximum number of ligands that can be attached to the metal; and k' + k "is the maximum number of ligands that can be attached to the metal.
In one aspect, (Y)101-Y102) Is a 2-phenylpyridine derivative. In another aspect, (Y)101-Y102) Is a carbene ligand. In another aspect, Met is selected from Ir, Pt, Os and Zn. In another aspect, the metal complex has a structure comparable to Fc+A minimum oxidation potential in solution of less than about 0.6V for/Fc coupling.
Non-limiting examples of HIL and HTL materials that can be used in OLEDs in combination with the materials disclosed herein, along with references disclosing those materials, are exemplified by the following: CN102702075, DE102012005215, EP01624500, EP0169861, EP01806334, EP01930964, EP01972613, EP01997799, EP02011790, EP02055700, EP02055701, EP1725079, EP2085382, EP2660300, EP650955, JP07-073529, JP2005112765, JP2007091, JP 2008021621687, JP2014-009196, KR 201188898, KR20130077473, TW 201139201139402, US06517957, US 2008220158242, US20030162053, US20050123751 751, US 20060282993, US 200602872 14579, US 201181874874, US20070278938, US 20080014014464 091091091, US20080106190, US 200907192605092385, US 12460352009071794392604335200356371798, WO 20120020120020135200353141563543544354435443544354435443544354435443544354435443544354435646, WO 200200352003520035563256325632563256325646, WO 20035200352003520035200435443544354435443544354435443544354435443544354435646, WO 200605646, WO 200605632563256325632563256325646, WO 2002002002002002002002002002002002002002004356325632563256325632563256325632563256325632563256325632563256325632567, WO 2004354435443435632563256325632563256325632563256325632563243544354434354435443544354435443544354435443544354435443541, WO 200200200200200200200200200200200200200200200200200200.
Figure BDA0002705770930001111
Figure BDA0002705770930001121
Figure BDA0002705770930001131
Figure BDA0002705770930001141
Figure BDA0002705770930001151
Figure BDA0002705770930001161
Figure BDA0002705770930001171
c)EBL:
An Electron Blocking Layer (EBL) may be used to reduce the number of electrons and/or excitons that leave the emissive layer. The presence of such a barrier layer in a device may result in substantially higher efficiency and/or longer lifetime compared to a similar device lacking a barrier layer. In addition, blocking layers can be used to limit the emission to the desired area of the OLED. In some embodiments, the EBL material has a higher LUMO (closer to the vacuum level) and/or higher triplet energy than the emitter closest to the EBL interface. In some embodiments, the EBL material has a higher LUMO (closer to the vacuum level) and/or higher triplet energy than one or more of the bodies closest to the EBL interface. In one aspect, the compound used in the EBL contains the same molecule or the same functional group as used in one of the hosts described below.
d) A main body:
the light-emitting layer of the organic EL device of the present disclosure preferably contains at least a metal complex as a light-emitting material, and may contain a host material using the metal complex as a dopant material. Examples of the host material are not particularly limited, and any metal complex or organic compound may be used as long as the triplet energy of the host is larger than that of the dopant. Any host material may be used with any dopant so long as the triplet criteria are met.
Examples of the metal complex used as the host preferably have the following general formula:
Figure BDA0002705770930001172
wherein Met is a metal; (Y)103-Y104) Is a bidentate ligand, Y103And Y104Independently selected from C, N, O, P and S; l is101Is another ligand; k' is an integer value from 1 to the maximum number of ligands that can be attached to the metal; and k' + k "is the maximum number of ligands that can be attached to the metal.
In one aspect, the metal complex is:
Figure BDA0002705770930001173
wherein (O-N) is a bidentate ligand having a metal coordinated to the O and N atoms.
In another aspect, Met is selected from Ir and Pt. In another aspect, (Y)103-Y104) Is a carbene ligand.
In one aspect, the host compound contains at least one selected from the group consisting of: a group consisting of aromatic hydrocarbon cyclic compounds such as: benzene, biphenyl, terphenyl, triphenylene, tetraphenylene, naphthalene, anthracene, phenalene, phenanthrene, fluorene, pyrene, perylene,
Figure BDA0002705770930001182
Perylene and azulene(ii) a A group consisting of aromatic heterocyclic compounds such as: dibenzothiophene, dibenzofuran, dibenzoselenophene, furan, thiophene, benzofuran, benzothiophene, benzoselenophene, carbazole, indolocarbazole, pyridylindole, pyrrolobipyridine, pyrazole, imidazole, triazole, oxazole, thiazole, oxadiazole, oxatriazole, dioxazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, triazine, oxazine, oxathiazine, oxadiazine, indole, benzimidazole, indazole, indolizine, benzoxazole, benzisoxazole, benzothiazole, quinoline, isoquinoline, cinnoline, quinazoline, quinoxaline, naphthyridine, phthalazine, pteridine, xanthene, acridine, phenazine, phenothiazine, phenoxazine, benzofuropyridine, furobipyridine, benzothienopyridine, thienobipyridine, benzoselenenopyridine, and selenenopyridine; and a group consisting of 2 to 10 cyclic structural units which are the same type or different types of groups selected from aromatic hydrocarbon ring groups and aromatic heterocyclic groups and are bonded to each other directly or via at least one of an oxygen atom, a nitrogen atom, a sulfur atom, a silicon atom, a phosphorus atom, a boron atom, a chain structural unit and an aliphatic ring group. Each option in each group may be unsubstituted or may be substituted with a substituent selected from the group consisting of: deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, aralkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphino, and combinations thereof.
In one aspect, the host compound contains at least one of the following groups in the molecule:
Figure BDA0002705770930001181
Figure BDA0002705770930001191
wherein R is101Selected from the group consisting of: hydrogen, deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, aralkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphino, and combinations thereof, and when it is aryl or heteroaryl, it has a similar definition to Ar mentioned above. k is an integer from 0 to 20 or from 1 to 20. X101To X108Independently selected from C (including CH) or N. Z101And Z102Independently selected from NR101O or S.
Non-limiting examples of host materials that can be used in OLEDs in combination with the materials disclosed herein are exemplified below, along with references disclosing those materials: EP2034538, EP2034538A, EP2757608, JP2007254297, KR20100079458, KR20120088644, KR20120129733, KR20130115564, TW201329200, US20030175553, US20050238919, US20060280965, US20090017330, US20090030202, US20090167162, US20090302743, US20090309488, US20100012931, US20100084966, US20100187984, US2010187984, US2012075273, US2012126221, US2013009543, US2013105787, US2013175519, US 001446, US 20148301503, US20140225088, US2014034914, US7154114, WO2001039234, WO 2004093203203203207, WO 2005014545454545452009020090455646, WO 2002012009020120090201902019072201200907220120020190722012002012002016072201200201200201200201607246, WO 20120020120020160722012002016072201200201200201607246, WO 200201200201200201200201200201200201200201200907220020120020120020120020120020120020120090729, WO 200201200201200201200201200201200201200201200201200201200201200201200201200201200201200201200201200200200201200201200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200,
Figure BDA0002705770930001201
Figure BDA0002705770930001211
Figure BDA0002705770930001221
Figure BDA0002705770930001231
Figure BDA0002705770930001241
e) other emitters:
one or more other emitter dopants may be used in combination with the compounds of the present invention. Examples of the other emitter dopant are not particularly limited, and any compound may be used as long as the compound is generally used as an emitter material. Examples of suitable emitter materials include, but are not limited to, compounds that can produce emission via phosphorescence, fluorescence, thermally activated delayed fluorescence (i.e., TADF, also known as E-type delayed fluorescence), triplet-triplet annihilation, or a combination of these processes.
Non-limiting examples of emitter materials that can be used in OLEDs in combination with the materials disclosed herein, along with references disclosing those materials, are exemplified below: CN103694277, CN1696137, EB01238981, EP01239526, EP01961743, EP1239526, EP1244155, EP1642951, EP1647554, EP1841834, EP1841834B, EP2062907, EP2730583, JP 201207440263, JP4478555, KR1020090133652, KR20120032054, KR20130043460, TW201332980, US0669959, US 200100916520, US20010019782, US20020034656, US 20030068568526, US20030072964, US 2003013865657, US 200501787878788, US 20020020020020120044673, US2005123791, US 2006052449 449, US20060008670, US20060065890, US 601696, US 6016016016012006012016016310204659, US 2012002012002012002012002012000477817781979, WO 20020120020120020120020020020020020020004778177819748, US 20120020020004779, WO 200200200201200201200200200200200201200778177819748, US 20020120004779, US 20120020120020120020120020020120020020020004779, US 2002012002002002002002002002002002002002002002002002002002012000477819748, US 200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200779, US 200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200779, US 200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200200779, US 20020020020020020020020020020020020020020020020020020020120020120020020020020020020020020020020020020020020020020020020020020020020043979, US 20020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020043979, US 20020020020020020020020020020020020020020020020020020020020020020020020020020020020043979, US 20020020020120020120020020020020020020020020020020020020020020020043979, US 20020020020020020020020020020020020120020120020020020020020020020020020020020020020020020020020020020020020020020020020020120020020020020020020020020020020020020020020020043979, US 20020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020020120020120020120020120043979, US 200200200200200200200200200200200200200200200200200200200200200200200200200200200, WO2012020327, WO2012163471, WO2013094620, WO2013107487, WO2013174471, WO2014007565, WO2014008982, WO2014023377, WO2014024131, WO2014031977, WO2014038456, WO 2014112450.
Figure BDA0002705770930001251
Figure BDA0002705770930001261
Figure BDA0002705770930001271
Figure BDA0002705770930001281
Figure BDA0002705770930001291
f)HBL:
Hole Blocking Layers (HBLs) may be used to reduce the number of holes and/or excitons that leave the emissive layer. The presence of such a barrier layer in a device may result in substantially higher efficiency and/or longer lifetime compared to a similar device lacking a barrier layer. In addition, blocking layers can be used to limit the emission to the desired area of the OLED. In some embodiments, the HBL material has a lower HOMO (farther from the vacuum level) and/or higher triplet energy than the emitter closest to the HBL interface. In some embodiments, the HBL material has a lower HOMO (farther from the vacuum level) and/or higher triplet energy than one or more of the hosts closest to the HBL interface.
In one aspect, the compound used in the HBL contains the same molecule or the same functional group as used for the host described above.
In another aspect, the compound used in HBL contains in the molecule at least one of the following groups:
Figure BDA0002705770930001301
wherein k is an integer from 1 to 20; l is101Is another ligand, and k' is an integer of 1 to 3.
g)ETL:
The Electron Transport Layer (ETL) may include a material capable of transporting electrons. The electron transport layer may be intrinsic (undoped) or doped. Doping may be used to enhance conductivity. Examples of the ETL material are not particularly limited, and any metal complex or organic compound may be used as long as it is generally used to transport electrons.
In one aspect, the compound used in the ETL contains in the molecule at least one of the following groups:
Figure BDA0002705770930001302
wherein R is101Selected from the group consisting of: hydrogen, deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, aralkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphino, and combinations thereof, which when aryl or heteroaryl has a similar definition to Ar described above. Ar (Ar)1To Ar3Have similar definitions as Ar mentioned above. k is an integer of 1 to 20. X101To X108Selected from C (including CH) or N.
In another aspect, the metal complex used in the ETL contains (but is not limited to) the following general formula:
Figure BDA0002705770930001311
wherein (O-N) or (N-N) is a bidentate ligand having a metal coordinated to atom O, N or N, N; l is101Is another ligand; k' is an integer value from 1 to the maximum number of ligands that can be attached to the metal.
Non-limiting examples of ETL materials that can be used in an OLED in combination with the materials disclosed herein, along with references disclosing those materials, are exemplified as follows: CN103508940, EP01602648, EP01734038, EP01956007, JP2004-022334, JP2005149918, JP2005-268199, KR0117693, KR20130108183, US20040036077, US20070104977, US2007018155, US20090101870, US20090115316, US20090140637, US 2009017959554, US2009218940, US2010108990, US2011156017, US2011210320, US2012193612, US2012214993, US 20140142014014925, US 201401492014927, US 2014028450284580, US 5666612, US 1508431, WO 200306093060979256, WO2007111263, WO2009148269, WO2010067894, WO2010072300, WO 201107070, WO 105373, WO 201303017, WO 201314545477, WO 2014545667, WO 201104376, WO2014104535, WO 2014535,
Figure BDA0002705770930001312
Figure BDA0002705770930001321
Figure BDA0002705770930001331
h) charge Generation Layer (CGL)
In tandem or stacked OLEDs, CGL plays a fundamental role in performance, consisting of an n-doped layer and a p-doped layer for injecting electrons and holes, respectively. Electrons and holes are supplied by the CGL and the electrodes. Electrons and holes consumed in the CGL are refilled by electrons and holes injected from the cathode and anode, respectively; subsequently, the bipolar current gradually reaches a steady state. Typical CGL materials include n and p conductivity dopants used in the transport layer.
In any of the above-mentioned compounds used in each layer of the OLED device, the hydrogen atoms may be partially or fully deuterated. Thus, any of the specifically listed substituents, such as (but not limited to) methyl, phenyl, pyridyl, and the like, can be in their non-deuterated, partially deuterated, and fully deuterated forms. Similarly, substituent classes (such as, but not limited to, alkyl, aryl, cycloalkyl, heteroaryl, etc.) can also be non-deuterated, partially deuterated, and fully deuterated forms thereof.
It should be understood that the various embodiments described herein are by way of example only and are not intended to limit the scope of the invention. For example, many of the materials and structures described herein may be substituted with other materials and structures without departing from the spirit of the invention. The invention as claimed may thus comprise variations of the specific examples and preferred embodiments described herein, as will be apparent to those skilled in the art. It should be understood that various theories as to why the invention works are not intended to be limiting.
E. Experimental data
Figure BDA0002705770930001341
2, 4-dichloro-5-iodopyridine (6.00g, 21.9mmol) and copper (I) iodide (8.34g, 43.8mmol) were dissolved in dry N, N-Dimethylformamide (DMF) (140mL) and the reaction mixture was bubbled with nitrogen for 15 minutes. Methyl 2, 2-difluoro-2- (fluorosulfonyl) acetate (5.6mL, 43.8mmoL) was then added, and the reaction mixture was heated at 100 ℃ for 3 hours. The mixture was cooled to room temperature (about 22 ℃), then diluted with water (100mL) and extracted with diethyl ether (3 × 100 mL). The combined organic extracts were washed with water (100mL), then brine (3 × 100mL), then dried over magnesium sulfate, and finally the solvent was removed in vacuo. 2, 4-dichloro-5- (trifluoromethyl) pyridine was obtained as a yellow oil (4.55g, 21.1mmol, 96%) and used in the next step without further purification.
Figure BDA0002705770930001342
In a 500mL 3-neck round-bottom flask equipped with a reflux condenser, 2, 4-dichloro-5- (trifluoromethyl) pyridine (4.55g, 21.1mmol), sodium carbonate (10.05g, 94.8mmol), 2- (4-tert-butyl-2-naphthyl) -4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan (6.21g, 20.0mmol) were dissolved in Dimethoxyethane (DME) (60mL) and water (12 mL). The mixture was then bubbled with nitrogen for 15 minutes, followed by addition of tetrakis (triphenylphosphine) palladium (0) (Pd (PPh)3)4) (1.22g, 1.05mmol) and degassed for 15 minutes. The reaction mixture was heated at 90 ℃ for 18 hours under nitrogen. The reaction mass is then cooled to room temperature (about 22 ℃) and distributed through a bed of silica gel, such as by Imersys Minerals California, Inc
Figure BDA0002705770930001343
Filtering with diatomite. The solvent was removed in vacuo and the crude product wasThe material was partitioned between brine (100mL) and ethyl acetate (100 mL). The aqueous phase was extracted with ethyl acetate (3 × 100mL) then combined with the organic extracts, then washed with water (100mL) then brine (100mL), then dried over magnesium sulfate, and the solvent was removed in vacuo. The resulting crude mixture was purified by flash chromatography on a standard silica gel column using a mixture of isohexane and ethyl acetate to give 2- (4- (tert-butyl) naphthalen-2-yl) -4-chloro-5- (trifluoromethyl) pyridine as a white solid (6.13g, 15.3mmol, 72%).
Figure BDA0002705770930001351
In a 500mL 3-necked round-bottomed flask equipped with a reflux condenser were placed 2- (4- (tert-butyl) naphthalen-2-yl) -4-chloro-5- (trifluoromethyl) pyridine (5.55g, 15.3mmol), 4-biphenylboronic acid (4.53g, 22.9mmol), tripotassium phosphate (9.71g, 45.8mmol) and dicyclohexyl (2',6' -dimethoxy- [1,1' -biphenyl)]-2-yl) phosphine (0.63g, 1.53mmol) was dissolved in toluene (60mL) and water (6 mL). The mixture was then bubbled with nitrogen for 15 minutes, followed by the addition of tris (dibenzylideneacetone) dipalladium (0) (Pd)2dba3) (0.70g, 0.763mmol) and degassed for a further 15 minutes. The resulting dark purple mixture was heated at 100 ℃ for 18 hours. The mixture was then allowed to cool to room temperature (about 22 ℃) and the solvent was removed in vacuo. The crude product was partitioned between water (100mL) and ethyl acetate (100mL) and the aqueous phase was extracted with ethyl acetate (3 × 100 mL). The combined organic extracts were washed with brine (100mL), dried over magnesium sulfate, and the solvent was removed in vacuo. The resulting crude mixture was purified by flash chromatography on a standard silica gel column using a mixture of isohexane and ethyl acetate, followed by recrystallization from isopropanol to give the product as a white solid (4.21g, 8.74mmol, 57%).
Figure BDA0002705770930001352
To the solution was added 2- (4- (tert-butyl) naphthalen-2-yl) -4-phenyl-5- (trifluoromethyl) pyridine (1.14g, 2.8)mmol, 1.6 equivalents) and iridium (III) chloride hydrate (650mg, 1.75mmol, 1.0 equivalents). The reaction mixture was bubbled with nitrogen for 10 minutes, then heated to 110 ℃ for 24 hours to form the intermediate μ -dichloride complex shown in the synthetic scheme above. After cooling to room temperature, 3, 7-diethylnonane-4, 6-dione (1.19g, 5.60mmol, 1.6 equiv.) and tetrahydrofuran (50mL) were added to the reaction mixture. The mixture was bubbled with nitrogen for 10 minutes. Powdered potassium carbonate (1.16g, 8.40mmol, 2.4 equiv.) was added and the reaction mixture was heated to 45 ℃ for 18 hours. The reaction mixture was then cooled to room temperature, concentrated under reduced pressure, and the residue was diluted with methanol (50mL) and water (50 mL). The red suspension was filtered and the solid was washed with methanol (50 mL). The resulting solid was dissolved in methylene chloride (150mL), dried over anhydrous sodium sulfate (30g), and then dry loaded onto a bed of silica gel (20g), such as distributed by Immunisie mining, Calif
Figure BDA0002705770930001363
On diatomaceous earth. The crude product was purified on silica gel (300g) eluting with a gradient of 0% to 25% dichloromethane/hexanes to give bis [ (2- (4- (tert-butyl) naphthalen-2-yl) -1' -yl) -4-phenyl-5- (trifluoromethyl) pyridin-1-yl]- (3, 7-diethylnonane-4, 6-dione-. kappa.2O, O') -iridium (III) (in two steps, 1.84g, 54%).
Figure BDA0002705770930001361
4- ([1,1' -biphenyl) is reacted with]A suspension of (E) -4-yl) -2- (4- (tert-butyl) naphthalen-2-yl) -5- (trifluoromethyl) pyridine (2.0g, 4.17mmol, 2.2 equiv.) and iridium (III) chloride hydrate (0.6g, 1.895mmol, 1.0 equiv.) in 2-ethoxyethanol (36mL) and deionized ultrafiltration (DIUF) water (12mL) was heated at 100 ℃ for 16 h. After cooling the reaction mixture to room temperature, DIUF water (50mL) was added and the suspension was filtered. The resulting intermediate μ -dichloride complex was obtained as a red solid, which was washed with water (50mL) and methanol (50mL) and then used directly in the next step. 3, 7-Diethylnonane-4, 6-dione (1.352g,6.37mmol, 2.0 equiv.) and powdered potassium carbonate (1.32g, 9.55mmol, 3.0 equiv.) were added to a suspension of the crude intermediate μ -dichloride complex shown in the above synthetic scheme (4.51g, estimated 3.18mmol, 1.0 equiv.) in methanol (40mL) and dichloromethane (40 mL). The reaction mixture was stirred at 42 ℃ for 16 hours. The crude reaction mixture was concentrated under reduced pressure, and the residue was diluted with DIUF water (100 mL). The slurry was filtered and the red solid residue was washed with methanol (100 mL). The crude residue was dissolved in a minimal amount of dichloromethane, adsorbed onto silica gel (24g) and purified on an intel (interchem) automatic chromatography system (80g sombrech technology silica gel cartridge) eluting with a gradient of 5% to 50% dichloromethane/hexane. The product was wet-milled with methanol (100mL) and dried under vacuum at about 50 ℃ for 16 hours to give bis [4- ([1,1' -biphenyl) as a red solid]-4-yl) -2- (4- (tert-butyl) naphthalen-2-yl) -1' -yl) -5- (trifluoromethyl) pyridin-1-yl]- (3, 7-diethyl-4, 6-nonanedionyl-k)2O, O') -iridium (III) (1.92g, 44% yield, 99.4% purity).
Figure BDA0002705770930001362
4- ([1,1' -biphenyl) is reacted with]A suspension of (4-yl) -2- (naphthalen-2-yl) -5- (trifluoromethyl) pyridine (2.81g, 6.6mmol, 2.2 equiv.) and iridium (III) chloride hydrate (0.95g, 3.0mmol, 1.0 equiv.) in 2-ethoxyethanol (30mL) and DIUF water (10mL) was heated at 100 ℃ for 16 h. After cooling to room temperature, DIUF water (25mL) was added. The resulting solid was filtered and washed with DIUF water (25mL) and methanol (3 × 25mL) to give the crude intermediate μ -dichloride complex shown in the synthetic scheme as a red solid. 3, 7-Diethylnonane-4, 6-dione (1.282g, 6.04mmol, 2.0 equiv.) and powdered potassium carbonate (1.252g, 9.06mmol, 3.0 equiv.) are added to a suspension of crude μ -dichloride complex (6.5g, estimated 3.02mmol, 1.0 equiv.) in methanol (50mL) and dichloromethane (50 mL). The reaction mixture was stirred at 42 ℃ for 16 hours. The resulting crude reaction mixture was concentrated under reduced pressure, and the residue was diluted with DIUF water (50 mL). The red solid was filtered and made up with methanol (3:)25mL) was washed. The crude residue was dissolved in a minimal amount of dichloromethane, adsorbed onto silica gel (100g) and purified on an intel automated chromatography system (220g soybu technical silica gel column) eluting with a gradient of 20% to 50% dichloromethane/hexane. The resulting product was wet-milled with refluxing methanol (250mL) and warm filtered. The solid was dried under vacuum at 50 ℃ for 16 hours to give bis [4- ([1,1' -biphenyl) as a red solid]-4-yl) - (2- (naphthalen-2-yl) -3' -yl) -5- (trifluoromethyl) pyridin-1-yl]- (3, 7-diethyl-4, 6-nonane-dione-k)2O, O') -iridium (III) (1.9g, 50% yield, 99.9% purity).
Figure BDA0002705770930001371
A suspension of 4, 6-bis (4- (tert-butyl) naphthalen-2-yl) pyrimidine (3.28g, 7.37mmol, 2.2 equiv.) in 2-ethoxyethanol (98mL) and DIUF water (32mL) was bubbled with nitrogen for ten minutes. Iridium (III) chloride hydrate (1.0g, 3.35mmol, 1.0 equiv) was added and the reaction mixture was heated at 100 ℃ for 16 h. The reaction mixture was cooled to room temperature, then DIUF water (100mL) was added and the solid was filtered. The crude intermediate μ -dichloride complex shown in the above synthetic scheme was obtained as a red solid, washed with DIUF water (500mL) and methanol (3 × 100mL) and then used directly in the next step.
To the crude di-mu-chloro-tetrakis [ (4- (4- (tert-butyl) -naphthalen-2-yl) -1' -yl) -6- (4- (tert-butyl) naphthalen-2-yl) pyrimidin-1-yl]To a suspension of diidium (III) (intermediate μ -dichloride complex) (about 3.35mmol, 1.0 equiv.) in methanol (200mL) and dichloromethane (150mL) was added 3, 7-diethylnonane-4, 6-dione (1.42g, 6.70mmol, 2.0 equiv.) and powdered potassium carbonate (1.39g, 10.05mmol, 3.0 equiv.). The reaction mixture was stirred at 40 ℃ for 16 hours. The reaction mixture was then concentrated under reduced pressure. The residue was adsorbed onto silica gel (120g) and purified on an intein automated system (220g soybu technology silica gel box) eluting with a gradient of 5% -50% dichloromethane/hexane over 45 minutes. The resulting product was wet-milled with methanol (250mL) to give bis [4- ((4- (tert-butyl) naphthalen-2-yl) -1' -yl) -6- (4- (tert-butyl) naphthalen-2-yl) -pyrimidin-2-yl]- (3, 7-diethyl-4, 6-nonanedionyl-k)2O, O') Iridium (III) (2.85g, 66% yield).
Figure BDA0002705770930001381
To the solution was added 4, 6-bis (naphthalen-2-yl) pyrimidine (2.09g, 6.30mmol, 1.8 equiv.) and iridium (III) chloride hydrate (1.297g, 3.5mmol, 1.0 equiv.). The reaction mixture was bubbled with nitrogen for 5 minutes, then heated at 75 ℃ for 18 hours to form an intermediate μ -dichloride complex. The reaction mixture was cooled and transferred to a 250mL 3-neck round bottom flask equipped with a thermocouple and reflux condenser. 3, 7-Diethylnonane-4, 6-dione (1.49g, 7.0mmol, 4.0 equiv.) and tetrahydrofuran (60mL) were added and the mixture was bubbled with nitrogen for 10 min. Powdered potassium carbonate (1.45g, 10.5mmol, 6.0 equiv.) was added and the reaction mixture was stirred at 45 ℃ for 17 hours. After cooling to room temperature, the reaction mixture was concentrated under reduced pressure. The residue was diluted with methanol (100mL) and water (50 mL). The red suspension was filtered and the solid was washed with methanol (50 mL). The crude solid was purified on silica gel (400g) eluting with a gradient of 0% to 15% tetrahydrofuran/hexane. The recovered impure product was wet-milled with a 1 to 10 mixture of dichloromethane and methanol (110mL) and filtered. The solid was repurified on silica gel (500g) eluting with a gradient of 0% to 15% tetrahydrofuran/hexane. The product was then wet milled with a 1 to 10 mixture of dichloromethane and methanol (110 mL). The solid was filtered and dried under vacuum at 45 ℃ for 2 hours to give bis [ (4- (naphthalen-2-yl) -3' -yl) -6- (naphthalen-2-yl) pyrimidin-3-yl) as a red solid]- (3, 7-diethylnonane-4, 6-dione-. kappa.2O, O') -iridium (III) (952mg, 26% yield over two steps).
Example of the device
All example devices were passed through high vacuum: (<10-7 torr) thermal evaporation. The anode electrode is
Figure BDA0002705770930001382
Indium Tin Oxide (ITO). Cathode made of
Figure BDA0002705770930001383
Liq (8-hydroxyquinoline lithium) followed by
Figure BDA0002705770930001384
Aluminum (Al). Immediately after fabrication, all devices were enclosed in a nitrogen glove box with epoxy-sealed glass covers: (<1ppm H2O and O2) And incorporating a desiccant into the interior of the package. The organic stack of the device example consisted of, in order: ITO surface as Hole Injection Layer (HIL)
Figure BDA0002705770930001385
LG101 (available from LG chemical company (LG Chem)); as Hole Transport Layers (HTL)
Figure BDA0002705770930001386
The HTM of (1); as Electron Blocking Layers (EBL)
Figure BDA0002705770930001387
The EBM of (1); containing RH as red host and 3% emitter
Figure BDA0002705770930001388
An emission layer (EML); and doped with 35% of ETM as Electron Transport Layer (ETL)
Figure BDA0002705770930001389
Liq (8-hydroxyquinoline lithium) of (1). Table 1 shows device layer thicknesses and materials.
TABLE 1 device layer materials and thicknesses
Figure BDA0002705770930001391
The chemical structure of the device material is shown below:
Figure BDA0002705770930001392
Figure BDA0002705770930001401
devices were manufactured using inventive example 1 and comparative examples 1 and 2. After fabrication, the device was tested for emission spectrum, electroluminescent efficiency, and power consumption. For this purpose, the samples were run at 10mA/cm using a 2-channel Keysight B2902A SMU2Is energized and measured using a Photo Research PR735 spectroradiometer. Collecting 380nm to 1080nm radiation intensity (W/str/cm)2) And integrated total photon count. Each device was then placed under a large area silicon photodiode for JVL scanning. Using the device at 10mA/cm2The integrated photon counting below converts the photodiode current into a photon count. The voltage is swept from 0 to 200mA/cm2The voltage of (c). The integrated total photon counts are used to calculate the EQE for each device. The results are summarized in table 2. The voltages and EQEs for the examples of the invention are reported as relative numbers normalized to the results of comparative example 2.
Table 2.
Figure BDA0002705770930001402
Table 2 is a summary of the efficacy of the electroluminescent devices evaluated. The inventive device (device 1) exhibited a saturated red color and a much narrower emission spectrum than that of device 3 using comparative example 2. In addition, the EQE of the device of the present invention is 1.3 times higher than that of device 3. The inventive device (device 1) exhibited more saturated colors and a higher EQE than device 2. Thus, the inventive device emits more saturated red light and exhibits improved current efficiency.
Photoluminescence (PL) spectra of the inventive and comparative compounds were measured in poly (methyl methacrylate) (PMMA) for inventive compound 2 and comparative compound 3. The values are shown in table 3 below.
Table 3.
Figure BDA0002705770930001403
Inventive example 2 exhibited a much narrower emission spectrum, while comparative example 3 exhibited a broad, slightly blue-shifted structural emission. In general, the FWHM of phosphorescent emitter complexes is broad, typically in the range of 60 to 100 nm. Achieving a narrow FWHM is a constantly sought goal. The narrower the FWHM, the better the color purity of the display application. In past OLED studies, narrowed line shapes have been slowly achieved on the nanometer scale. The current results are significantly unexpected results.

Claims (20)

1. A first ligand L comprising formula IAThe compound of (a) to (b),
Figure FDA0002705770920000011
wherein:
ring B is a 5-or 6-membered carbocyclic or heterocyclic ring, which can be further fused;
X1、X2and X3Each independently is CRAOr N;
r is a 5 or 6 membered carbocyclic or heterocyclic ring which can be further fused or substituted;
with the proviso that
(1) When ring B is a non-fused 6-membered ring, X1And X2Is N, and X3Is C;
(2) when ring B is a fused 6-membered ring, ring B has the structure of formula II;
Figure FDA0002705770920000012
wherein:
the wavy line indicates the point of connection to ring a;
Q1、Q2、Q3、Q4、Q5and Q6Each independently is C or N; and is
When the restriction condition (2) applies, at least one of the following conditions is true:
(I)X1、X2and X3Is N; or
(II) R is two or more fused or non-fused 5-or 6-membered carbocyclic or heterocyclic rings which can be further fused or substituted;
wherein R isBAnd RCEach independently represents a single to a maximum number of permissible substitutions, or no substitution;
each RA、RBAnd RCIndependently hydrogen or a substituent selected from the group consisting of: deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, oxyboronyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphino, and combinations thereof;
wherein L isACoordination to metal M via a designated dotted line;
wherein M is selected from the group consisting of: ir, Os, Pt, Pd, Cu, Ag and Au;
wherein M is capable of coordinating to other ligands;
wherein L isACapable of engaging with other ligands to form a tridentate, tetradentate, pentadentate, or hexadentate ligand; and is
Wherein any two substituents can be joined or fused to form a ring.
2. The compound of claim 1, wherein each RA、RBAnd RCIndependently hydrogen or a substituent selected from the group consisting of: deuterium, fluorine, alkyl, cycloalkyl, heteroalkyl, alkoxy, aryloxy, amino, silyl, oxyboronyl, alkenyl, cycloalkenyl, heteroalkenyl, aryl, heteroaryl, nitrile, isonitrile, thio, and combinations thereof.
3. The compound of claim 1, wherein R is a substituted or unsubstituted 6-or 5-membered aromatic or heteroaromatic ring.
4. The compound of claim 1, wherein R is selected from the group consisting of: imidazole, oxazole, thiazole, pyridine, phenyl, biphenyl, carbazole, benzofuran, benzothiophene, dibenzofuran, dibenzothiophene, substituted variants thereof, and combinations thereof.
5. The compound of claim 1, wherein R is two or more fused 5-or 6-membered carbocyclic or heterocyclic rings, which can be further fused or substituted.
6. The compound of claim 1, wherein R is two or more non-fused 5-or 6-membered carbocyclic or heterocyclic rings, which can be further substituted.
7. The compound of claim 1, wherein ring B has the structure of formula II; and wherein Q1、Q2、Q3、Q4、Q5And Q6Each of which is C.
8. The compound of claim 1, wherein ring B has the structure of formula II; and wherein Q1、Q2、Q3、Q4、Q5And Q6Is N.
9. The compound of claim 1, wherein ring B is a 5-membered ring.
10. The compound of claim 1, wherein LAHaving a structure selected from the group consisting of:
Figure FDA0002705770920000031
11. the compound of claim 1, wherein ring B has a structure selected from the group consisting of:
Figure FDA0002705770920000032
wherein for each n, the substituent RD、RE、RFAnd RGThe following were chosen:
Figure FDA0002705770920000041
Figure FDA0002705770920000051
Figure FDA0002705770920000061
Figure FDA0002705770920000071
Figure FDA0002705770920000081
Figure FDA0002705770920000091
wherein R is1To R30Has the following structure:
Figure FDA0002705770920000092
Figure FDA0002705770920000093
12. the compound of claim 1, wherein R has a structure selected from the group consisting of:
Figure FDA0002705770920000094
Figure FDA0002705770920000101
Figure FDA0002705770920000102
which can be further substituted;
wherein each Y is independently selected from the group consisting of: s, O, NRCy1、CRCy2RCy3And SiRCy4RCy5
Wherein each Q is independently CRCyOr N; and is
Wherein R isCy、RCy1、RCy2、RCy3、RCy4And RCy5Each of which is independently hydrogen or a substituent selected from the group consisting of: deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, oxyboronyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphino, and combinations thereof.
13. The compound of claim 1, wherein the ligand LA is selected from the group consisting of:
Figure FDA0002705770920000111
Figure FDA0002705770920000121
Figure FDA0002705770920000131
Figure FDA0002705770920000141
Figure FDA0002705770920000151
Figure FDA0002705770920000161
Figure FDA0002705770920000171
Figure FDA0002705770920000181
Figure FDA0002705770920000191
Figure FDA0002705770920000201
Figure FDA0002705770920000211
Figure FDA0002705770920000221
Figure FDA0002705770920000231
Figure FDA0002705770920000241
Figure FDA0002705770920000251
Figure FDA0002705770920000261
Figure FDA0002705770920000271
Figure FDA0002705770920000281
Figure FDA0002705770920000291
Figure FDA0002705770920000301
Figure FDA0002705770920000311
wherein i is an integer from 1 to 3600, and for each LAi-m,RH、RIAnd G is defined as follows:
Figure FDA0002705770920000312
Figure FDA0002705770920000321
Figure FDA0002705770920000331
Figure FDA0002705770920000341
Figure FDA0002705770920000351
Figure FDA0002705770920000361
Figure FDA0002705770920000371
Figure FDA0002705770920000381
Figure FDA0002705770920000391
Figure FDA0002705770920000401
Figure FDA0002705770920000411
Figure FDA0002705770920000421
Figure FDA0002705770920000431
Figure FDA0002705770920000441
Figure FDA0002705770920000451
Figure FDA0002705770920000461
Figure FDA0002705770920000471
Figure FDA0002705770920000481
Figure FDA0002705770920000491
Figure FDA0002705770920000501
Figure FDA0002705770920000511
Figure FDA0002705770920000521
Figure FDA0002705770920000531
Figure FDA0002705770920000541
Figure FDA0002705770920000551
Figure FDA0002705770920000561
wherein R isH1To RH30Has the following structure:
Figure FDA0002705770920000562
Figure FDA0002705770920000563
Figure FDA0002705770920000571
Figure FDA0002705770920000572
and is
Wherein G is1To G20Has the following structure:
Figure FDA0002705770920000573
Figure FDA0002705770920000574
Figure FDA0002705770920000581
14. the compound of claim 1, wherein the compound has a formula selected from the group consisting of: m (L)A)p(LB)q(LC)r、Ir(LA)3、Ir(LA)(LB)2、Ir(LA)2(LB)、Ir(LA)2(LC) And Ir (L)A)(LB)(LC) Wherein L isBAnd LCEach is a bidentate ligand; wherein L isA、LBAnd LCAre different from each other; wherein p is 1,2 or 3; q is 0, 1 or 2; r is 0, 1 or 2; and wherein p + q + r is the oxidation state of the metal M.
15. The compound of claim 14, wherein LBAnd LCEach independently selected from the group consisting of:
Figure FDA0002705770920000582
Figure FDA0002705770920000591
wherein:
Y1to Y13Each of which is independently selected from the group consisting of C and N;
y' is selected from the group consisting of: BR (BR)e、NRe、PRe、O、S、Se、C=O、S=O、SO2、CReRf、SiReRfAnd GeReRf
ReAnd RfCan be fused or joined to form a ring;
each Ra、Rb、RcAnd RdIndependently represent the allowed replacements of zero, single, or up to the maximum number of their associated rings;
Ra1、Rb1、Rc1、Ra、Rb、Rc、Rd、Reand RfEach of which is independently hydrogen or a substituent selected from the group consisting of: deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, oxyboronyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acid, ester, nitrile, isonitrile, thio, sulfinyl, sulfonyl, phosphino, and combinations thereof; and is
Ra、Rb、RcAnd RdCan be fused or joined to form a ring or form a multidentate ligand.
16. The compound of claim 14, wherein the compound is selected from the group consisting of:
(a) the compound has the formula Ir (L)Ai-m)3Wherein i is an integer from 1 to 3600; m is an integer from 1 to 344; and the compound is selected from the group consisting of Ir (L)A1-1)3To Ir (L)A3600-344)3A group of compounds;
(b) the compound has the formula Ir (L)Ai-m)(LBk)2Wherein i is an integer from 1 to 3600; m is an integer from 1 to 344; k is an integer from 1 to 264; and the compound is selected from the group consisting of Ir (L)A1-1)(LB1)2To Ir (L)A3600-344)(LB264)2A group of compounds;
(c) the compound has the formula Ir (L)Ai-m)2(LBk) Wherein i is an integer from 1 to 3600; m is an integer from 1 to 344; k is an integer from 1 to 264; and the compound is selected from the group consisting of Ir (L)A1-1)2(LB1) To Ir (L)A3600-344)2(LB264) A group of compounds; and is
(d) The compound has Ir (L)Ai-m)2(LCj-I) Or Ir (L)Ai-m)2(LCj-II) Wherein i is an integer from 1 to 3600; m is an integer from 1 to 344; j is an integer from 1 to 1416; and the compound is selected from the group consisting of Ir (L)A1-1)2(LC1-I) To Ir (L)A3600-344)2(LC1416-I) And Ir (L)A1-1)2(LC1-II) To Ir (L)A3600-344)2(LC1416-II) A group of compounds;
each LBkHas a structure defined as:
Figure FDA0002705770920000601
Figure FDA0002705770920000611
Figure FDA0002705770920000621
Figure FDA0002705770920000631
Figure FDA0002705770920000641
Figure FDA0002705770920000651
Figure FDA0002705770920000661
Figure FDA0002705770920000671
Figure FDA0002705770920000681
Figure FDA0002705770920000691
wherein each LCj-IHas a formula based on
Figure FDA0002705770920000692
The structure of (1); and is
Each LCj-IIHas a formula based on
Figure FDA0002705770920000693
In respect of L, whereinCj-IAnd LCj-IIEach L inCj,R1′And R2′Each independently defined as follows:
Figure FDA0002705770920000694
Figure FDA0002705770920000701
Figure FDA0002705770920000711
Figure FDA0002705770920000721
Figure FDA0002705770920000731
Figure FDA0002705770920000741
Figure FDA0002705770920000751
Figure FDA0002705770920000761
Figure FDA0002705770920000771
wherein R isD1To RD246Has the following structure:
Figure FDA0002705770920000772
Figure FDA0002705770920000781
Figure FDA0002705770920000791
Figure FDA0002705770920000801
Figure FDA0002705770920000811
17. the compound of claim 1, wherein the compound is selected from the group consisting of:
Figure FDA0002705770920000812
Figure FDA0002705770920000821
Figure FDA0002705770920000831
Figure FDA0002705770920000841
Figure FDA0002705770920000851
18. an Organic Light Emitting Device (OLED), comprising:
an anode;
a cathode; and
an organic layer disposed between the anode and the cathode,
wherein the organic layer comprises the compound of claim 1.
19. The OLED of claim 18 wherein the organic layer further comprises a host, wherein host comprises at least one chemical moiety selected from the group consisting of: triphenylene, carbazole, indolocarbazole, dibenzothiophene, dibenzofuran, dibenzoselenophene, 5, 9-dioxa-13 b-boronaphtho [3,2,1-de ] anthracene, aza-triphenylene, aza-carbazole, aza-indolocarbazole, aza-dibenzothiophene, aza-dibenzofuran, aza-dibenzoselenophene, and aza- (5, 9-dioxa-13 b-boronaphtho [3,2,1-de ] anthracene).
20. A consumer product comprising an organic light emitting device, OLED, comprising:
an anode;
a cathode; and
an organic layer disposed between the anode and the cathode, wherein the organic layer comprises the compound of claim 1.
CN202011044860.7A 2019-09-26 2020-09-28 Organic electroluminescent material and device Pending CN112552352A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962906305P 2019-09-26 2019-09-26
US62/906,305 2019-09-26
US202063010815P 2020-04-16 2020-04-16
US63/010,815 2020-04-16
US17/022,151 2020-09-16
US17/022,151 US20210098717A1 (en) 2019-09-26 2020-09-16 Organic electroluminescent materials and devices

Publications (1)

Publication Number Publication Date
CN112552352A true CN112552352A (en) 2021-03-26

Family

ID=75042792

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011044860.7A Pending CN112552352A (en) 2019-09-26 2020-09-28 Organic electroluminescent material and device

Country Status (1)

Country Link
CN (1) CN112552352A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150014659A1 (en) * 2013-07-11 2015-01-15 Samsung Display Co., Ltd. Iridium complex and organic light-emitting device including the same
US20150053937A1 (en) * 2013-08-23 2015-02-26 Samsung Display Co., Ltd. Organic light-emitting device
CN107759639A (en) * 2017-10-23 2018-03-06 云南民族大学 LED with can blue light excite the preparation of orange red cationic iridium (III) complex
US20190074458A1 (en) * 2017-09-05 2019-03-07 Samsung Electronics Co., Ltd. Organometallic compound, organic light-emitting device including the organometallic compound, and diagnostic composition including the organometallic compound

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150014659A1 (en) * 2013-07-11 2015-01-15 Samsung Display Co., Ltd. Iridium complex and organic light-emitting device including the same
US20150053937A1 (en) * 2013-08-23 2015-02-26 Samsung Display Co., Ltd. Organic light-emitting device
US20190074458A1 (en) * 2017-09-05 2019-03-07 Samsung Electronics Co., Ltd. Organometallic compound, organic light-emitting device including the organometallic compound, and diagnostic composition including the organometallic compound
CN107759639A (en) * 2017-10-23 2018-03-06 云南民族大学 LED with can blue light excite the preparation of orange red cationic iridium (III) complex

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ATSUTOSHI YAMADA等: "Flipping of the coordinated triazine moiety in Cu(I)–L2 and the small electronic factor, κel, for direct outer-sphere cross reactions: syntheses, crystal structures and redox behaviour of copper(II)/(I)–L2 complexes (L = 3-(2-pyridyl)-5, 6-diphenyl-1, 2, 4-triazine)", 《DALTON TRANS.》, vol. 22, pages 13979 - 13990 *
MAI-YAN YUEN等: "Synthesis, Photophysical and Electrophosphorescent Properties of Fluorene- Based Platinum(II) Complexes", 《CHEM. EUR. J.》, vol. 16, pages 14131 - 14141 *

Similar Documents

Publication Publication Date Title
CN110890472A (en) Organic electroluminescent material and device
CN112300216A (en) Organic electroluminescent material and device
CN112409416A (en) Organic electroluminescent material and device
KR20210037590A (en) Organic electroluminescent materials and diveces
KR20240095141A (en) Organic electroluminescent materials and devices
CN112390828A (en) Organic electroluminescent material and device
CN111606956A (en) Organic electroluminescent material and device
CN114524851A (en) Organic electroluminescent material and device
CN114230613A (en) Organic electroluminescent material and device
CN110563768A (en) Organic electroluminescent material and device
CN114057799A (en) Organic electroluminescent material and device
CN112279874A (en) Organic electroluminescent material and device
KR20210004861A (en) Organic electroluminescent materials and devices
CN115536706A (en) Organic electroluminescent material and device
CN115433239A (en) Organic electroluminescent material and device
CN115703811A (en) Organic electroluminescent material and device
CN112341498B (en) Organic electroluminescent material and device
CN114853815A (en) Organic electroluminescent material and device
CN114539323A (en) Organic electroluminescent material and device
CN114315867A (en) Fast phosphors using HP2H ligand
CN114349793A (en) Organic electroluminescent material and device
CN111793093A (en) Organic electroluminescent material and device
CN112175012A (en) Organic electroluminescent material and device
CN112390827A (en) Organic electroluminescent material and device
CN112552352A (en) Organic electroluminescent material and device

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination